Library Use Only

RM301.45 .A66 1995 Jun Suppl

Approved drug products with
therapeutic equivalence
C:355661 M:174736 O:12937927

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

Library Use Only

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Cumulative Supplement 6

JUNE 1995

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

CUMULATIVE SUPPLEMENT 6
JUNE 1995

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 15th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing shaded print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 15th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 16th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required

to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation

of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BOOTS PHARMACEUTICALS INC (BOOTS)	KNOLL PHARMACEUTICAL COMPANY SUB BASF CORPORATION (KNOLL PHARM)
BRIAN PHARMACEUTICALS INC (BRIAN)	HYGENICS PHARMACEUTICALS INC (HYGENICS)
DORSEY LABORATORIES DIV SANDOZ WANDER INC (DORSEY)	SANDOZ CONSUMER HEALTH CARE GROUP DIV SANDOZ PHARMACEUTICALS CORP (SANDOZ)
MILES PHARMACEUTICAL DIV MILES INC (MILES)	BAYER CORPORATION (BAYER)
PENNEX PHARMACEUTICALS INC (PENNEX)	MORTON GROVE PHARMACEUTICALS INC (MORTON GROVE)
TAP PHARMACEUTICALS INC (TAP PHARMS)	TAP HOLDINGS INC (TAP HOLDINGS)

1.4 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is now available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1994) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1994	MAR 1995	JUN 1995	SEP 1995
DRUG PRODUCTS LISTED	9141	9195	9221	
SINGLE SOURCE	2178 (23.8%)	2186 (23.8%)	2186 (23.7%)	
MULTISOURCE	6963 (76.2%)	7009 (76.2%)	7035 (76.3%)	
THERAPEUTICALLY EQUIVALENT	6330 (69.2%)	6380 (69.4%)	6399 (69.4%)	
NOT THERAPEUTICALLY EQUIVALENT	453 (5.0%)	453 (4.9%)	452 (4.9%)	
EXCEPTIONS[1]	180 (2.0%)	176 (1.9%)	184 (2.0%)	
NEW MOLECULAR ENTITIES APPROVED	--	2	10	
NUMBER OF APPLICANTS	534	541	559	

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

		ACEBUTOLOL HCL			
AB		MYLAN	EQ 200MG BASE	N74288 001	APR 24, 1995
AB			EQ 400MG BASE	N74288 002	APR 24, 1995
		SECTRAL			
AB		WYETH AYERST	EQ 200MG BASE	N18917 001	DEC 28, 1984
AB	+		EQ 400MG BASE	N18917 003	DEC 28, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

			BUTALBITAL, ACETAMINOPHEN AND CAFFEINE			
>ADD<	AB		WEST WARD PHARM	325MG;50MG;40MG	N89718 001	JUN 12, 1995
>ADD<						

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

>ADD<			**ACETAMINOPHEN AND CODEINE PHOSPHATE**			
>ADD<	AA		BARRE	120MG/5ML;12MG/5ML	N85861 001	
>DLT<			**APAP W/ CODEINE**			
>DLT<	AA		BARRE	120MG/5ML;12MG/5ML	N85861 001	

TABLET; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA		KV PHARM	300MG;30MG	N85288 001	
AA			300MG;60MG	N85365 001	
			325MG;15MG	N85364 001	
			325MG;45MG	N85363 001	
	@		300MG;30MG	N85288 001	
	@		300MG;60MG	N85365 001	
	@		325MG;15MG	N85364 001	
	@		325MG;45MG	N85363 001	
AA		MIKART	650MG;30MG	N89231 001	MAR 03, 1986
	+		650MG;30MG	N89231 001	MAR 03, 1986
		PHENAPHEN-650 W/ CODEINE			
AA	+	ROBINS AH	650MG;30MG	N85856 001	
	@		650MG;30MG	N85856 001	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

			ANEXSIA			
AA			BOEHRINGER MANNHEIM	500MG;5MG	N89160 001	APR 23, 1987
AA			KING PHARMS	500MG;5MG	N89160 001	APR 23, 1987
			ANEXSIA 7.5/650			
AA			BOEHRINGER MANNHEIM	650MG;7.5MG	N89725 001	SEP 30, 1987
AA			KING PHARMS	650MG;7.5MG	N89725 001	SEP 30, 1987
			HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
>DLT<	AA		HALSEY	500MG;5MG	N89554 001	JUN 12, 1987
>DLT<						
>ADD<		@		500MG;5MG	N89554 001	JUN 12, 1987
>ADD<						
>ADD<	AA		KING PHARMS	500MG;5MG	N40084 002	JUN 01, 1995
>ADD<						
>ADD<	AA			750MG;7.5MG	N40084 001	JUN 01, 1995
>ADD<						

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

			OXYCET			
>DLT<	AA		HALSEY	325MG;5MG	N87463 001	DEC 07, 1983
>DLT<						
>ADD<	AA		MALLINCKRODT	325MG;5MG	N87463 001	DEC 07, 1983
>ADD<						

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

		ACETAZOLAMIDE SODIUM			
AP		BEDFORD	EQ 500MG BASE/VIAL	N40089 001	FEB 28, 1995
		DIAMOX			
AP	+	STORZ OPHTHALM	EQ 500MG BASE/VIAL	N09388 001	DEC 05, 1990

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

		ACETYLCYSTEINE			
AN		DUPONT MERCK	10%	N71364 001 MAY 01, 1989	
AN			20%	N71365 001 MAY 01, 1989	
AN		FAULDING	10%	N71364 001 MAY 01, 1989	> ADD > > ADD >
AN			20%	N71365 001 MAY 01, 1989	> ADD > > ADD >

ADENOSINE

INJECTABLE; INJECTION

		ADENOSCAN			
	+	MEDCO RES	3MG/ML	N20059 001 MAY 18, 1995	

ALBUTEROL SULFATE

SYRUP; ORAL

		PROVENTIL			
> DLT > > DLT > > ADD > > ADD >	AA	SCHERING	EQ 2MG BASE/5ML	N18062 001 JAN 19, 1983	
> DLT > > DLT > > ADD > > ADD >	AA	+	EQ 2MG BASE/5ML	N18062 001 JAN 19, 1983	

AMIKACIN SULFATE

INJECTABLE; INJECTION

		AMIKACIN			
AP		DUPONT MERCK	EQ 50MG BASE/ML	N63350 001 JUL 30, 1993	
AP			EQ 250MG BASE/ML	N63350 002 JUL 30, 1993	
AP	+	ELKINS SINN	EQ 50MG BASE/ML	N63274 001 MAY 18, 1992	
AP	+		EQ 250MG BASE/ML	N63275 001 MAY 18, 1992	
		AMIKACIN SULFATE			
AP		ELKINS SINN	EQ 50MG BASE/ML	N63274 001 MAY 18, 1992	> DLT > > ADD >
AP			EQ 250MG BASE/ML	N63275 001 MAY 18, 1992	

AMIKACIN SULFATE

INJECTABLE; INJECTION

		AMIKACIN SULFATE			
AP		FAULDING	EQ 50MG BASE/ML	N63350 001 JUL 30, 1993	
AP			EQ 250MG BASE/ML	N63350 002 JUL 30, 1993	
AP		SANOFI WINTHROP	EQ 250MG BASE/ML	N64098 001 JUN 26, 1995	
AP			EQ 250MG BASE/ML	N64099 001 JUN 20, 1995	
		AMIKIN			
AP		APOTHECON	EQ 50MG BASE/ML	N62311 001	
AP	+		EQ 50MG BASE/ML	N62311 001	
AP			EQ 250MG BASE/ML	N62311 002	
AP	+		EQ 250MG BASE/ML	N62311 002	
	@		EQ 50MG BASE/ML	N62562 001 SEP 20, 1984	
	@		EQ 250MG BASE/ML	N62562 002 SEP 20, 1984	
	@	BRISTOL	EQ 50MG BASE/ML	N62562 001 SEP 20, 1984	
	@		EQ 250MG BASE/ML	N62562 002 SEP 20, 1984	

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@	APOTHECON	EQ 5MG BASE/ML	N50618 002 NOV 30, 1987	
@		EQ 10MG BASE/ML	N50618 001 NOV 30, 1987	
@	BRISTOL	EQ 5MG BASE/ML	N50618 002 NOV 30, 1987	
@		EQ 10MG BASE/ML	N50618 001 NOV 30, 1987	

AMINOPHYLLINE

INJECTABLE; INJECTION

		AMINOPHYLLINE			
AP		FUJISAWA	25MG/ML	N88407 001 JAN 25, 1984	
	@		25MG/ML	N88407 001 JAN 25, 1984	
AP		KING PHARMS	25MG/ML	N86606 001	> DLT > > ADD >
	@		25MG/ML	N86606 001	

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

AB	**ROXANE**	**150MG**	**N86090 001**	
	@	150MG	N86090 001	

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

	CIBA GEIGY	EQ 2.5MG BASE;10MG	N20364 002	> ADD >
			MAR 03, 1995	> ADD >
		EQ 5MG BASE;10MG	N20364 003	> ADD >
			MAR 03, 1995	> ADD >
	+	EQ 5MG BASE;20MG	N20364 004	> ADD >
			MAR 03, 1995	> ADD >

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	CONSOLIDATED PHARM	**250MG**	**N62058 001**	> ADD >
AB		**500MG**	**N62058 002**	> ADD >

COMOX

AB	COPANOS	**250MG**	**N62058 001**	> ADD >
AB		**500MG**	**N62058 002**	> ADD >

POLYMOX

AB	APOTHECON	**250MG**	**N63099 001**	> ADD >
			MAR 20, 1992	> ADD >
AB		**500MG**	**N63099 002**	
			MAR 20, 1992	

TRIMOX

AB	APOTHECON	**250MG**	**N63099 001**	
			MAR 20, 1992	
AB		**500MG**	**N63099 002**	
			MAR 20, 1992	

POWDER FOR RECONSTITUTION; ORAL

AMOXICILLIN

AB	CONSOLIDATED PHARM	**125MG/5ML**	**N62059 001**	> DLT >
AB		**250MG/5ML**	**N62059 002**	> DLT >

AMOXICILLIN TRIHYDRATE

AB	COPANOS	**125MG/5ML**	**N62059 001**	> DLT >
AB		**250MG/5ML**	**N62059 002**	> DLT >

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

AP	GENSIA	**50MG/VIAL**	**N64062 001**	
			MAR 31, 1995	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	APOTHECON	**EQ 125MG BASE/VIAL**	**N61395 001**	> ADD >
AP		**EQ 125MG BASE/VIAL**	**N62860 001**	> ADD >
			FEB 05, 1988	> ADD >
AP		**EQ 250MG BASE/VIAL**	**N61395 002**	> ADD >
AP		**EQ 250MG BASE/VIAL**	**N62860 002**	> ADD >
			FEB 05, 1988	> ADD >
AP		**EQ 500MG BASE/VIAL**	**N61395 003**	> ADD >
AP		**EQ 500MG BASE/VIAL**	**N62860 003**	> ADD >
			FEB 05, 1988	> ADD >
AP		**EQ 1GM BASE/VIAL**	**N61395 004**	> ADD >
AP		**EQ 1GM BASE/VIAL**	**N62738 001**	> ADD >
			FEB 19, 1987	> ADD >
AP		**EQ 1GM BASE/VIAL**	**N62860 004**	> ADD >
			FEB 05, 1988	> ADD >
AP		**EQ 2GM BASE/VIAL**	**N61395 005**	> ADD >
AP		**EQ 2GM BASE/VIAL**	**N62738 002**	> ADD >
			FEB 19, 1987	> ADD >
AP		**EQ 2GM BASE/VIAL**	**N62860 005**	> ADD >
			FEB 05, 1988	> ADD >
AP	+	**EQ 10GM BASE/VIAL**	**N61395 006**	> ADD >
	@ CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	N61936 005	
	@	EQ 250MG BASE/VIAL	N61936 001	
	@	EQ 500MG BASE/VIAL	N61936 002	
	@	EQ 1GM BASE/VIAL	N61936 003	
	@	EQ 2GM BASE/VIAL	N61936 004	
	@ COPANOS	EQ 125MG BASE/VIAL	N61936 005	
	@	EQ 250MG BASE/VIAL	N61936 001	
	@	EQ 500MG BASE/VIAL	N61936 002	
	@	EQ 1GM BASE/VIAL	N61936 003	
	@	EQ 2GM BASE/VIAL	N61936 004	

PRINCIPEN

AP	APOTHECON	**EQ 125MG BASE/VIAL**	**N61395 001**	> DLT >
AP		**EQ 125MG BASE/VIAL**	**N62860 001**	> DLT >
			FEB 05, 1988	> DLT >
AP		**EQ 250MG BASE/VIAL**	**N61395 002**	> DLT >
AP		**EQ 250MG BASE/VIAL**	**N62860 002**	> DLT >
			FEB 05, 1988	> DLT >

AMPICILLIN SODIUM

INJECTABLE; INJECTION

> DLT >		PRINCIPEN			
> DLT >	AP	APOTHECON	EQ 500MG BASE/VIAL	N61395 003	
> DLT >	AP		EQ 500MG BASE/VIAL	N62860 003	
> DLT >				FEB 05, 1988	
> DLT >	AP		EQ 1GM BASE/VIAL	N61395 004	
> DLT >	AP		EQ 1GM BASE/VIAL	N62738 001	
> DLT >				FEB 19, 1987	
> DLT >	AP		EQ 1GM BASE/VIAL	N62860 004	
> DLT >				FEB 05, 1988	
> DLT >	AP		EQ 2GM BASE/VIAL	N61395 005	
> DLT >	AP		EQ 2GM BASE/VIAL	N62738 002	
> DLT >				FEB 19, 1987	
> DLT >	AP		EQ 2GM BASE/VIAL	N62860 005	
> DLT >				FEB 05, 1988	
> DLT >	AP	*	EQ 10GM BASE/VIAL	N61395 006	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

	AMPICILLIN TRIHYDRATE			
AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	
AB	COPANOS	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	

POWDER FOR RECONSTITUTION; ORAL

	AMPICILLIN TRIHYDRATE			
AB	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
AB	COPANOS	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
	POLYCILLIN			
AB	* BRISTOL	EQ 500MG BASE/5ML	N50308 003	
	+	EQ 500MG BASE/5ML	N50308 003	

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A			
* CIBA VISION	0.5%;0.05%	N18746 001	APR 30, 1990

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL AND ASPIRIN			
AB	STEVENS J	325MG;400MG	N81145 001	JAN 31, 1995

ATENOLOL

TABLET; ORAL

	ATENOLOL			
AB	COPLEY PHARM	50MG	N74120 001	FEB 24, 1995
AB		100MG	N74120 002	FEB 24, 1995
AB	LEMMON	50MG	N74056 001	JAN 18, 1995
AB		100MG	N74056 002	JAN 18, 1995
AB	MARTEC	50MG	N74127 001	FEB 21, 1995
AB		100MG	N74127 002	FEB 21, 1995

ATOVAQUONE

SUSPENSION; ORAL

	MEPRON			
	+ BURROUGHS WELLCOME	750MG/5ML	N20500 001	FEB 08, 1995

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

	AZATHIOPRINE SODIUM			
AP	BEDFORD	EQ 100MG BASE/VIAL	N74419 001	MAR 31, 1995
	IMURAN			
AP	+ BURROUGHS WELLCOME	EQ 100MG BASE/VIAL	N17391 001	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		ADV REMEDIES	500 UNITS/GM; 10,000 UNITS/GM	N64028 001 JAN 30, 1995
AT		BAUSCH AND LOMB	500 UNITS/GM; 10,000 UNITS/GM	N64046 001 JAN 26, 1995

POLYSPORIN

AT	+	BURROUGHS WELLCOME	500 UNITS/GM; 10,000 UNITS/GM	N61229 001

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

	+	APOTHECON	10MG	N12164 003
	+	SQUIBB	10MG	N12164 003

NATURETIN-2.5

	@	APOTHECON	2.5MG	N12164 001
	@	SQUIBB	2.5MG	N12164 001

NATURETIN-5

		APOTHECON	5MG	N12164 002
		SQUIBB	5MG	N12164 002

BENTONITE; SULFUR

POWDER; TOPICAL

BENSULFOID

> DLT >		@ POYTHRESS	66.64%;33.32%	N02918 001

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLOL

AP		DUPONT MERCK	50MG/ML	N17954 001
AP		FAULDING	50MG/ML	N17954 001

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP		BEDFORD	0.25MG/ML	N74441 001 JAN 27, 1995

BUMETANIDE

TABLET; ORAL

BUMETANIDE

AB		ZENITH LABS	0.5MG	N74225 001 APR 24, 1995
AB			1MG	N74225 002 APR 24, 1995
AB			2MG	N74225 003 APR 24, 1995

BUMEX

AB		ROCHE	0.5MG	N18225 002 FEB 28, 1983
AB			1MG	N18225 001 FEB 28, 1983
AB	+		2MG	N18225 003 JUN 14, 1985

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

MARCAINE HCL

AP	+	SANOFI WINTHROP	0.25%	N16964 001
AP	+		0.5%	N16964 006
AP	+		0.75%	N16964 009
AP	+	STERLING WINTHROP	0.25%	N16964 001
AP	+		0.5%	N16964 006
AP	+		0.75%	N16964 009

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HCL W/ EPINEPHRINE

AP	+	SANOFI WINTHROP	0.25%;0.0091MG/ML	N16964 004
AP	+		0.5%;0.0091MG/ML	N16964 008
AP	+		0.75%;0.0091MG/ML	N16964 010
AP	+	STERLING WINTHROP	0.25%;0.0091MG/ML	N16964 004
AP	+		0.5%;0.0091MG/ML	N16964 008
AP	+		0.75%;0.0091MG/ML	N16964 010

CALCITONIN, SALMON

INJECTABLE; INJECTION

CALCITONIN-SALMON

AP		ASTRA	200 IU/ML	N73690 001 APR 14, 1995

CAPTOPRIL

TABLET; ORAL

		CAPOTEN		
AB		BRISTOL MYERS SQUIBB	12.5MG	N18343 005 JAN 17, 1985
AB			25MG	N18343 002
AB			50MG	N18343 001
AB	+		100MG	N18343 003
		CAPTOPRIL		
AB		APOTHECON	12.5MG	N74472 001 MAR 31, 1995
AB			25MG	N74472 002 MAR 31, 1995
AB			50MG	N74472 003 MAR 31, 1995
AB			100MG	N74472 004 MAR 31, 1995

CARBACHOL

SOLUTION; INTRAOCULAR

		CARBASTAT		
AT		CIBA	0.01%	N73677 001 APR 28, 1995
		MIOSTAT		
AT	+	ALCON	0.01%	N16968 001

CARBIDOPA; LEVODOPA

TABLET; ORAL

			CARBIDOPA AND LEVODOPA		
> ADD >	AB		GENEVA PHARMS	10MG;100MG	N73586 001 JUN 29, 1995
> ADD >					
> ADD >	AB			25MG;100MG	N73587 001 JUN 29, 1995
> ADD >					
> ADD >	AB			25MG;250MG	N73620 001 JUN 29, 1995
> ADD >					

CEFACLOR

CAPSULE; ORAL

		CECLOR		
AB	+	LILLY	EQ 250MG BASE	N50521 001
AB			EQ 250MG BASE	N62205 001
AB	+		EQ 500MG BASE	N50521 002

CEFACLOR

CAPSULE; ORAL

		CECLOR		
AB		LILLY	EQ 500MG BASE	N62205 002
		CEFACLOR		
AB		LEDERLE	EQ 250MG BASE	N64107 001 APR 27, 1995
AB			EQ 500MG BASE	N64107 002 APR 27, 1995
AB		ZENITH LABS	EQ 250MG BASE	N64061 001 APR 27, 1995
AB			EQ 500MG BASE	N64061 002 APR 27, 1995

POWDER FOR RECONSTITUTION; ORAL

		CECLOR		
AB	+	LILLY	EQ 125MG BASE/5ML	N50522 001
AB			EQ 125MG BASE/5ML	N62206 001
AB	+		EQ 187MG BASE/5ML	N62206 003 APR 20, 1988
AB	+		EQ 250MG BASE/5ML	N50522 002
AB			EQ 250MG BASE/5ML	N62206 002
AB	+		EQ 375MG BASE/5ML	N62206 004 APR 20, 1988
		CEFACLOR		
AB		LEDERLE	EQ 125MG BASE/5ML	N64114 001 APR 28, 1995
AB			EQ 187MG BASE/5ML	N64115 001 APR 28, 1995
AB			EQ 250MG BASE/5ML	N64116 001 APR 28, 1995
AB			EQ 375MG BASE/5ML	N64110 001 APR 28, 1995
AB		ZENITH LABS	EQ 125MG BASE/5ML	N64087 001 APR 28, 1995
AB			EQ 187MG BASE/5ML	N64086 001 APR 28, 1995
AB			EQ 250MG BASE/5ML	N64085 001 APR 28, 1995
AB			EQ 375MG BASE/5ML	N64070 001 APR 28, 1995

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

		MANDOL		
	+	LILLY	EQ 500MG BASE/VIAL	N50504 001

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL			
@ LILLY	EQ 500MG BASE/VIAL	N50504 001	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

> ADD >		**CEFAZOLIN SODIUM**		
> ADD >	AP	APOTHECON	**EQ 500MG BASE/VIAL**	**N62831 001**
> ADD >				DEC 09, 1988
> ADD >	AP		**EQ 1GM BASE/VIAL**	**N62831 002**
> ADD >				DEC 09, 1988
> ADD >	AP		**EQ 10GM BASE/VIAL**	**N62831 003**
> ADD >				SEP 25, 1992
	AP	ELKINS SINN	**EQ 250MG BASE/VIAL**	**N62807 001**
				JAN 12, 1988
	AP		**EQ 500MG BASE/VIAL**	**N62807 002**
				JAN 12, 1988
	AP		**EQ 1GM BASE/VIAL**	**N62807 003**
				JAN 12, 1988
	AP		**EQ 5GM BASE/VIAL**	**N62807 004**
				JAN 12, 1988
	AP		**EQ 10GM BASE/VIAL**	**N62807 005**
				JAN 12, 1988
	AP		**EQ 20GM BASE/VIAL**	**N62807 006**
				JAN 12, 1988
	@		EQ 250MG BASE/VIAL	N62807 001
				JAN 12, 1988
	@		EQ 500MG BASE/VIAL	N62807 002
				JAN 12, 1988
	@		EQ 1GM BASE/VIAL	N62807 003
				JAN 12, 1988
	@		EQ 5GM BASE/VIAL	N62807 004
				JAN 12, 1988
	@		EQ 10GM BASE/VIAL	N62807 005
				JAN 12, 1988
	@		EQ 20GM BASE/VIAL	N62807 006
				JAN 12, 1988
> DLT >		**ZOLICEF**		
> DLT >	AP	APOTHECON	**EQ 500MG BASE/VIAL**	**N62831 001**
> DLT >				DEC 09, 1988
> DLT >	AP		**EQ 1GM BASE/VIAL**	**N62831 002**
> DLT >				DEC 09, 1988
> DLT >	AP		**EQ 10GM BASE/VIAL**	**N62831 003**
> DLT >				SEP 25, 1992

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID		
PFIZER	EQ 1GM BASE/VIAL	N63333 001
		MAR 31, 1995
	EQ 2GM BASE/VIAL	N63333 002
		MAR 31, 1995

CEFORANIDE

INJECTABLE; INJECTION

PRECEF		
APOTHECON	500MG/VIAL	N62579 001
		NOV 26, 1984
	1GM/VIAL	N62579 002
		NOV 26, 1984
	2GM/VIAL	N62579 003
		NOV 26, 1984
	10GM/VIAL	N62579 004
		NOV 26, 1984
	20GM/VIAL	N62579 005
		NOV 26, 1984
BRISTOL	500MG/VIAL	N62579 001
		NOV 26, 1984
	1GM/VIAL	N62579 002
		NOV 26, 1984
	2GM/VIAL	N62579 003
		NOV 26, 1984
	10GM/VIAL	N62579 004
		NOV 26, 1984
	20GM/VIAL	N62579 005
		NOV 26, 1984

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
+	MERCK SHARP DOHME	EQ 20MG BASE/ML	N50581 002
			SEP 20, 1984
+		EQ 40MG BASE/ML	N50581 001
			SEP 20, 1984
@		EQ 20MG BASE/ML	N50581 002
			SEP 20, 1984
@		EQ 40MG BASE/ML	N50581 001
			SEP 20, 1984

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

		ROCEPHIN		
AP	+	ROCHE	EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984
AP	+		EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984
AP	+		EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984
	+		EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984
	+		EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984
	+		EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984

CEFUROXIME SODIUM

INJECTABLE; INJECTION

		KEFUROX		
AP	+	LILLY	EQ 7.5GM BASE/VIAL	N62591 003 DEC 17, 1987
AP			EQ 7.5GM BASE/VIAL	N62591 003 DEC 17, 1987
		ZINACEF		
AP		GLAXO	EQ 7.5GM BASE/VIAL	N50558 004 OCT 23, 1986
AP	+		EQ 7.5GM BASE/VIAL	N50558 004 OCT 23, 1986

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL

		CEPHALEXIN		
AB		APOTHECON	EQ 125MG BASE/5ML	N62986 001 APR 18, 1991
AB			EQ 250MG BASE/5ML	N62987 001 JUL 25, 1989
AB		SQUIBB MARK	EQ 125MG BASE/5ML	N62986 001 APR 18, 1991
AB			EQ 250MG BASE/5ML	N62987 001 JUL 25, 1989

CEPHRADINE

CAPSULE; ORAL

		VELOSEF		
AB	+	APOTHECON	250MG	N61764 001
AB	+		500MG	N61764 002
AB	+	ERSANA	250MG	N61764 001
AB	+		500MG	N61764 002

INJECTABLE; INJECTION

		VELOSEF		
	+	APOTHECON	250MG/VIAL	N61976 001
	+		500MG/VIAL	N61976 002
	+		1GM/VIAL	N61976 004
	+		2GM/VIAL	N61976 003
	+		4GM/VIAL	N61976 005
	+	SQUIBB	250MG/VIAL	N61976 001
	+		500MG/VIAL	N61976 002
	+		1GM/VIAL	N61976 004
	+		2GM/VIAL	N61976 003
	+		4GM/VIAL	N61976 005

POWDER FOR RECONSTITUTION; ORAL

		VELOSEF '125'		
AB	+	APOTHECON	125MG/5ML	N61763 001
AB	+	ERSANA	125MG/5ML	N61763 001
		VELOSEF '250'		
AB	+	APOTHECON	250MG/5ML	N61763 002
AB	+	ERSANA	250MG/5ML	N61763 002

CHLORAMPHENICOL

CAPSULE; ORAL

		MYCHEL		
AB		ARMENPHARM	250MG	N60851 001
AB		RACHELLE	250MG	N60851 001

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

		CHLORPHENIRAMINE MALEATE		
AP		STERIS	10MG/ML	N83593 001
			100MG/ML	N86095 001
		@	10MG/ML	N83593 001
		@	100MG/ML	N86095 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL

AP	STERIS	25MG/ML	N85591 001	
	@	25MG/ML	N85591 001	

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

AB	LEMMON	100MG	N88768 001 OCT 11, 1984	> ADD >
	@	100MG	N88768 001 OCT 11, 1984	> ADD >

GLUCAMIDE

AB	LEMMON	250MG	N88641 001 OCT 11, 1984	> ADD >
	@	250MG	N88641 001 OCT 11, 1984	> ADD >

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL
CHOLYBAR

+	PARKE DAVIS	EQ 4GM RESIN/BAR	N71621 001 MAY 26, 1988	> ADD >
		EQ 4GM RESIN/BAR	N71739 001 MAY 26, 1988	> ADD >
	@	EQ 4GM RESIN/BAR	N71621 001 MAY 26, 1988	> ADD >
	@	EQ 4GM RESIN/BAR	N71739 001 MAY 26, 1988	> ADD >

TABLET; ORAL
QUESTRAN

+	BRISTOL MYERS SQUIBB	EQ 1GM RESIN	N73403 001 APR 28, 1994	
	@	EQ 1GM RESIN	N73403 001 APR 28, 1994	

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	GENEVA PHARMS	200MG	N74100 001 JAN 31, 1995	

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	GENEVA PHARMS	300MG	N74100 002 JAN 31, 1995	
AB		400MG	N74100 003 JAN 31, 1995	
AB		800MG	N74100 004 JAN 31, 1995	
AB	LEK LJUBLJANA	200MG	N74250 001 JUN 29, 1995	
AB		300MG	N74250 002 JUN 29, 1995	
AB		400MG	N74250 003 JUN 29, 1995	
AB		800MG	N74250 004 JUN 29, 1995	
AB	LEMMON	200MG	N74365 001 FEB 28, 1995	
AB		300MG	N74365 002 FEB 28, 1995	
AB		400MG	N74365 003 FEB 28, 1995	
AB		800MG	N74365 004 FEB 28, 1995	
AB	MOVA	300MG	N74340 001 JUN 23, 1995	
AB		400MG	N74340 002 JUN 23, 1995	
AB		800MG	N74339 001 JUN 23, 1995	
AB	ZENITH LABS	200MG	N74401 001 MAY 30, 1995	
AB		300MG	N74401 002 MAY 30, 1995	
AB		400MG	N74401 003 MAY 30, 1995	
AB		800MG	N74402 001 MAY 30, 1995	

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	ABBOTT	EQ 300MG BASE/2ML	N74344 001 JAN 31, 1995	

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CIMETIDINE HCL			
AP	ABBOTT	EQ 300MG BASE/2ML	N74345 001	JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74422 001	JAN 31, 1995

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

	CLEOCIN			
	UPJOHN	EQ 1% BASE	N50537 002	FEB 22, 1994

SWAB; TOPICAL

	CLEOCIN			
	UPJOHN	EQ 1% BASE	N50537 002	FEB 22, 1994

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

	EMBELINE			
AB	DPT	0.05%	N74221 001	MAR 31, 1995

CLOTRIMAZOLE

SOLUTION; TOPICAL

	CLOTRIMAZOLE			
AT	LEMMON	1%	N73306 001	FEB 28, 1995

CLOXACILLIN SODIUM

CAPSULE; ORAL

> ADD >		CLOXACILLIN SODIUM			
> ADD >	AB	+ APOTHECON	EQ 250MG BASE	N61452 001	
> ADD >	AB	+	EQ 500MG BASE	N61452 002	
> DLT >		TEGOPEN			
> DLT >	AB	+ APOTHECON	EQ 250MG BASE	N61452 001	
> DLT >	AB	+	EQ 500MG BASE	N61452 002	

CORTICOTROPIN

INJECTABLE; INJECTION

	ACTH			
AP	PARKE DAVIS	40 UNITS/VIAL	N08317 004	
	@	40 UNITS/VIAL	N08317 004	

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC

	CROLOM			
AT	BAUSCH AND LOMB	4%	N74443 001	JAN 30, 1995
	OPTICROM			
AT	+ FISONS	4%	N18155 001	OCT 03, 1984

CYANOCOBALAMIN

INJECTABLE; INJECTION

	CYANOCOBALAMIN			
	@ WARNER CHILCOTT	1MG/ML	N07085 002	
	RUBRAMIN PC			
AP	+ SQUIBB	0.1MG/ML	N06799 002	
	@	0.1MG/ML	N06799 002	
	SYTOBEX			
AP	PARKE DAVIS	1MG/ML	N07085 002	

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

	CYCLOBENZAPRINE HCL			
AB	BARR	10MG	N73541 001	MAY 23, 1995

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

	CYPROHEPTADINE HCL			
AA	ASCOT	4MG	N87685 001	OCT 25, 1982
	@	4MG	N87685 001	OCT 25, 1982

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL

AP	CETUS BEN VENUE	EQ 20MG BASE/VIAL	N64103 001	FEB 03, 1995

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DDAVP

+	RHONE POULENC	0.015MG/ML	N18938 002	APR 25, 1995

SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE

+	RHONE POULENC RORER	0.15MG/INH	N20355 001	MAR 07, 1994

STIMATE

+	RHONE POULENC RORER	0.15MG/INH	N20355 001	MAR 07, 1994

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGEN

AB	+	ORGANON	0.15MG;0.03MG	N20071 001	DEC 10, 1992
	@		0.15MG;0.03MG	N20071 001	DEC 10, 1992

ORTHO-CEPT

AB		JOHNSON RW	0.15MG;0.03MG	N20301 001	DEC 14, 1992
			0.15MG;0.03MG	N20301 001	DEC 14, 1992

DEXAMETHASONE

AEROSOL; TOPICAL
DECASPRAY

+	MERCK SHARP DOHME	0.4%	N12731 002	
+		0.04%	N12731 002	

TABLET; ORAL
HEXADROL

BP	ORGANON	0.5MG	N12675 004	

DEXAMETHASONE

TABLET; ORAL
HEXADROL

BP	ORGANON	0.75MG	N12675 007	
BP		1.5MG	N12675 009	
@		0.5MG	N12675 004	
@		0.75MG	N12675 007	
@		1.5MG	N12675 009	

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
ZINECARD

+	PHARMACIA	EQ 250MG BASE/VIAL	N20212 001	MAY 26, 1995
+		EQ 500MG BASE/VIAL	N20212 002	MAY 26, 1995

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 2.5% IN PLASTIC CONTAINER

	MCGAW	2.5GM/100ML	N19626 001	FEB 02, 1988
@		2.5GM/100ML	N19626 001	FEB 02, 1988

DEXTROSE 7.7% IN PLASTIC CONTAINER

	MCGAW	7.7GM/100ML	N19626 003	FEB 02, 1988
@		7.7GM/100ML	N19626 003	FEB 02, 1988

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

AP	FUJISAWA	5MG/ML	N70662 001	JUN 25, 1986
@		5MG/ML	N70662 001	JUN 25, 1986

DICLOFENAC POTASSIUM

TABLET; ORAL

	CATAFLAM			
	GEIGY	25MG		N20142 001 NOV 24, 1993
@		25MG		N20142 001 NOV 24, 1993

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

> ADD >		DICLOFENAC SODIUM		
> ADD >	AB	ROXANE	25MG	N74391 001 JUN 29, 1995
> ADD >				
> ADD >	AB		50MG	N74391 002 JUN 29, 1995
> ADD >				
> ADD >	AB		75MG	N74391 003 JUN 29, 1995
> ADD >				
		VOLTAREN		
> ADD >	AB +	GEIGY	25MG	N19201 001 JUL 28, 1988
> ADD >				
> ADD >	AB +		50MG	N19201 002 JUL 28, 1988
> ADD >				
> ADD >	AB +		75MG	N19201 003 JUL 28, 1988
> ADD >				

DICLOXACILLIN SODIUM

CAPSULE; ORAL

> ADD >		DICLOXACILLIN SODIUM		
> ADD >	AB	APOTHECON	EQ 250MG BASE	N61454 001
> ADD >	AB		EQ 500MG BASE	N61454 003
> ADD >			EQ 125MG BASE	N61454 002
> DLT >		DYNAPEN		
> DLT >	AB	APOTHECON	EQ 250MG BASE	N61454 001
> DLT >	AB		EQ 500MG BASE	N61454 003
> DLT >	AB		EQ 125MG BASE	N61454 002
> DLT >				

POWDER FOR RECONSTITUTION; ORAL

> ADD >		DICLOXACILLIN SODIUM		
> ADD >	AB	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001
> DLT >		DYNAPEN		
> DLT >	AB	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

		DILTIAZEM HCL		
AB		LEMMON	30MG	N74185 001 MAY 31, 1995
AB			60MG	N74185 002 MAY 31, 1995
AB			90MG	N74185 003 MAY 31, 1995
AB			120MG	N74185 004 MAY 31, 1995
AB		ZENITH LABS	30MG	N74168 001 MAR 03, 1995
AB			60MG	N74168 002 MAR 03, 1995
AB			90MG	N74168 003 MAR 03, 1995
AB			120MG	N74168 004 MAR 03, 1995

DIMENHYDRINATE

INJECTABLE; INJECTION

		DIMENHYDRINATE		
AP		STERIS	50MG/ML	N83531 001
@			50MG/ML	N83531 001

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL

		CERVIDIL		
	+	CONTROLLED THERAP	10MG	N20411 001 MAR 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

		DIPHENHYDRAMINE HCL		
AA		WEST WARD PHARM	50MG	N83567 001
@			50MG	N83567 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DIPIVEFRIN HCL

AT		BAUSCH AND LOMB	0.1%	N74188 001 MAY 19, 1995

> ADD > DIRITHROMYCIN

> ADD > TABLET, DELAYED RELEASE; ORAL
> ADD > DYNABAC
> ADD > + LILLY 250MG N50678 001
> ADD > JUN 19, 1995

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DEPAKOTE

+	ABBOTT	EQ 125MG BASE	N19680 001 SEP 12, 1989
+		EQ 125MG VALPROIC ACID	N19680 001 SEP 12, 1989

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE

	ABBOTT	EQ 125MG BASE	N18723 003 OCT 26, 1984
		EQ 250MG BASE	N18723 001 MAR 10, 1983
+		EQ 500MG BASE	N18723 002 MAR 10, 1983
		EQ 125MG VALPROIC ACID	N18723 003 OCT 26, 1984
		EQ 250MG VALPROIC ACID	N18723 001 MAR 10, 1983
+		EQ 500MG VALPROIC ACID	N18723 002 MAR 10, 1983

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL

AP		ASTRA	EQ 12.5MG BASE/ML	N74098 001 FEB 21, 1995
AP		SANOFI WINTHROP	EQ 12.5MG BASE/ML	N74292 001 FEB 16, 1995

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
INTROPIN

AP	+	DUPONT MERCK	40MG/ML	N17395 001
AP	+		80MG/ML	N17395 002
AP	+		160MG/ML	N17395 003
AP	+	FAULDING	40MG/ML	N17395 001
AP	+		80MG/ML	N17395 002
AP	+		160MG/ML	N17395 003

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DOXORUBICIN HCL

AP		PHARMACHEMIE (NL)	2MG/ML	N63336 001 FEB 28, 1995
AP			200MG/100ML	N63336 004 FEB 28, 1995

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE MONOHYDRATE

+		VINTAGE PHARMS	EQ 100MG BASE	N50641 001 DEC 29, 1989

MONODOX

+		OCLASSEN	EQ 100MG BASE	N50641 001 DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

AB		PVT FORM	EQ 50MG BASE	N62631 001 JUL 24, 1986
AB			EQ 100MG BASE	N62631 002 JUL 24, 1986
	@		EQ 50MG BASE	N62631 001 JUL 24, 1986
	@		EQ 100MG BASE	N62631 002 JUL 24, 1986

DROPERIDOL

INJECTABLE; INJECTION

	DROPERIDOL			
AP	DUPONT MERCK	2.5MG/ML	N71645 001	APR 07, 1988
AP	FAULDING	2.5MG/ML	N71645 001	APR 07, 1988

EDETATE DISODIUM

INJECTABLE; INJECTION

	SODIUM VERSENATE			
	+ 3M	200MG/ML	N10573 001	
	@	200MG/ML	N10573 001	

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC			
AB	+ PARKE DAVIS	250MG	N62338 001	
AB		250MG	N62618 001	SEP 25, 1985
AB	+	250MG	N62618 001	SEP 25, 1985
	@	250MG	N62338 001	

TABLET, DELAYED RELEASE; ORAL

	ROBIMYCIN			
AB	ROBINS AH	250MG	N61633 001	
	@	250MG	N61633 001	

ERYTHROMYCIN ESTOLATE

DROPS; ORAL

	ILOSONE		
	+ DISTA	EQ 100MG BASE/ML	N61894 003

SUSPENSION/DROPS; ORAL

	ILOSONE		
	+ DISTA	EQ 100MG BASE/ML	N61894 003

ERYTHROMYCIN ETHYLSUCCINATE

DROPS; ORAL

	PEDIAMYCIN		
	+ ROSS LABS	EQ 100MG BASE/2.5ML	N62305 002

SUSPENSION; ORAL

	WYAMYCIN E		
AB	WYETH AYERST	EQ 200MG BASE/5ML	N62123 002
AB		EQ 400MG BASE/5ML	N62123 001
	@	EQ 200MG BASE/5ML	N62123 002
	@	EQ 400MG BASE/5ML	N62123 001

SUSPENSION/DROPS; ORAL

	PEDIAMYCIN		
	+ ROSS LABS	EQ 100MG BASE/2.5ML	N62305 002

ERYTHROMYCIN STEARATE

TABLET; ORAL

	ETHRIL 250		
AB	SQUIBB	EQ 250MG BASE	N61605 001
	@	EQ 250MG BASE	N61605 001
	ETHRIL 500		
AB	SQUIBB	EQ 500MG BASE	N61605 002
	@	EQ 500MG BASE	N61605 002

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	VIVELLE		
BX	CIBA GEIGY	0.05MG/24HR	N20323 002 OCT 28, 1994
BX		0.1MG/24HR	N20323 004 OCT 28, 1994
		0.0375MG/24HR	N20323 001 OCT 28, 1994
		0.075MG/24HR	N20323 003 OCT 28, 1994
BX	NOVEN	0.05MG/24HR	N20323 002 OCT 28, 1994
BX		0.1MG/24HR	N20323 004 OCT 28, 1994
		0.0375MG/24HR	N20323 001 OCT 28, 1994
		0.075MG/24HR	N20323 003 OCT 28, 1994

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

OVCON-35				
+	BRISTOL MYERS SQUIBB	0.035MG;0.4MG	N18127 001	
+	MEAD JOHNSON	0.035MG;0.4MG	N18127 001	
OVCON-50				
@	BRISTOL MYERS SQUIBB	0.05MG;1MG	N18128 001	
+	MEAD JOHNSON	0.05MG;1MG	N18128 001	

TABLET; ORAL-28

OVCON-35			
	BRISTOL MYERS SQUIBB	0.035MG;0.4MG	N17716 001
	MEAD JOHNSON	0.035MG;0.4MG	N17716 001
OVCON-50			
	BRISTOL MYERS SQUIBB	0.05MG;1MG	N17576 001
	MEAD JOHNSON	0.05MG;1MG	N17576 001

ETOPOSIDE

INJECTABLE; INJECTION

	ETOPOSIDE			
>ADD< AP	GENSIA	20MG/ML	N74510 001	
>ADD<			JUN 29, 1995	
	TOPOSAR			
AP	PHARMACIA	20MG/ML	N74166 001	
			FEB 27, 1995	

FENOFIBRATE

CAPSULE; ORAL

LIPIDIL				
+	LABS FOURNIER	100MG	N19304 001	
			DEC 31, 1993	
@		100MG	N19304 001	
			DEC 31, 1993	

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF				
+	APOTHECON	0.1MG	N10060 001	
+	SQUIBB	0.1MG	N10060 001	

FLUNISOLIDE

SPRAY, METERED; NASAL

NASALIDE				
BX +	SYNTEX	0.025MG/INH	N18148 001	
NASAREL				
BX +	SYNTEX	0.025MG/INH	N20409 001	
			MAR 08, 1995	

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT +	HAMILTON PHARMA CA	0.01%	N12787 004	
AT +		0.025%	N12787 002	
AT +		0.025%	N12787 005	
+		0.2%	N16161 002	
	SYNALAR			
AT +	SYNTEX	0.01%	N12787 004	
AT +		0.025%	N12787 002	
	SYNALAR-HP			
+	SYNTEX	0.2%	N16161 002	
	SYNEMOL			
AT +	SYNTEX	0.025%	N12787 005	

OINTMENT; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT +	HAMILTON PHARMA CA	0.025%	N13960 001	
	SYNALAR			
AT +	SYNTEX	0.025%	N13960 001	

SOLUTION; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT +	HAMILTON PHARMA CA	0.01%	N15296 001	
	SYNALAR			
AT +	SYNTEX	0.01%	N15296 001	

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE			
AB +	HAMILTON PHARMA CA	0.05%	N16908 002	
	FLUOCINONIDE EMOLLIENT BASE			
AB	HAMILTON PHARMA CA	0.05%	N16908 003	
>ADD<	FLUOCINONIDE EMULSIFIED BASE			
>ADD< AB	NMC	0.05%	N74204 001	
>ADD<			JUN 13, 1995	

FLUOCINONIDE

CREAM; TOPICAL

		LIDEX		
AB	+	SYNTEX	0.05%	N16908 002
		LIDEX-E		
AB		SYNTEX	0.05%	N16908 003

GEL; TOPICAL

		FLUOCINONIDE		
AB	+	HAMILTON PHARMA CA	0.05%	N17373 001
		LIDEX		
AB	+	SYNTEX	0.05%	N17373 001

OINTMENT; TOPICAL

		FLUOCINONIDE		
AB	+	HAMILTON PHARMA CA	0.05%	N16909 002
		LIDEX		
AB	+	SYNTEX	0.05%	N16909 002

SOLUTION; TOPICAL

		FLUOCINONIDE		
AT		FOUGERA	0.05%	N72934 001 FEB 27, 1995
AT	+	HAMILTON PHARMA CA	0.05%	N18849 001 APR 06, 1984
		LIDEX		
AT	+	SYNTEX	0.05%	N18849 001 APR 06, 1984

FLURBIPROFEN

TABLET; ORAL

		FLURBIPROFEN		
AB		LEMMON	100MG	N74431 001 MAY 31, 1995
AB		NOVOPHARM	50MG	N74405 002 MAY 24, 1995
AB			100MG	N74405 001 MAY 24, 1995
AB		ZENITH LABS	50MG	N74411 001 MAY 31, 1995
AB			100MG	N74411 002 MAY 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

		FLURBIPROFEN SODIUM		
AT		BAUSCH AND LOMB	0.03%	N74447 001 JAN 04, 1995
		OCUFEN		
AT	+	ALLERGAN	0.03%	N19404 001 DEC 31, 1986

FOSINOPRIL SODIUM

TABLET; ORAL

		MONOPRIL		
	+	BRISTOL MYERS SQUIBB	20MG	N19915 003 MAY 16, 1991
			20MG	N19915 003 MAY 16, 1991
	+		40MG	N19915 004 MAR 28, 1995

GEMFIBROZIL

CAPSULE; ORAL

		GEMFIBROZIL		
AB	+	MYLAN	300MG	N73466 001 JAN 25, 1993
	@		300MG	N73466 001 JAN 25, 1993
AB		PUREPAC PHARM	300MG	N72929 001 JAN 29, 1993
	@		300MG	N72929 001 JAN 29, 1993
		LOPID		
AB	+	PARKE DAVIS	300MG	N18422 002
	@		300MG	N18422 002

TABLET; ORAL

		GEMFIBROZIL		
AB		CHELSEA LABS	600MG	N74442 001 APR 28, 1995
AB		MYLAN	600MG	N74452 001 FEB 16, 1995

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

		GENTAMICIN SULFATE		
	AT	ALCON	**EQ 0.3% BASE**	N62196 001

GLIPIZIDE

TABLET; ORAL

		GLIPIZIDE		
> ADD >	**AB**	ALPHAPHARM	**5MG**	**N74438 001**
> ADD >				JUN 20, 1995
> ADD >	**AB**		**10MG**	**N74438 002**
> ADD >				JUN 20, 1995
	AB	GENEVA PHARMS	**5MG**	**N74305 001**
				APR 07, 1995
	AB		**10MG**	**N74305 002**
				APR 07, 1995
> ADD >	**AB**	INVAMED	**5MG**	**N74542 001**
> ADD >				JUN 20, 1995
> ADD >	**AB**		**10MG**	**N74542 002**
> ADD >				JUN 20, 1995
	AB	WATSON LABS	**5MG**	**N74223 001**
				FEB 27, 1995
	AB		**10MG**	**N74223 002**
				FEB 27, 1995

GLYBURIDE

TABLET; ORAL

		GLUBATE		
		@ HOECHST ROUSSEL	1.5MG	N20055 001
				APR 17, 1992
		@	3MG	N20055 002
				APR 17, 1992
		GLYBURIDE (MICRONIZED)		
	AB	HOECHST ROUSSEL	**1.5MG**	**N20055 001**
				APR 17, 1992
	AB		**3MG**	**N20055 002**
				APR 17, 1992
		GLYNASE		
	AB	UPJOHN	**1.5MG**	**N20051 001**
				MAR 04, 1992
	AB		**3MG**	**N20051 002**
				MAR 04, 1992

GLYCINE

SOLUTION; IRRIGATION

		GLYCINE 1.5% IN PLASTIC CONTAINER		
	AT	BAXTER	**1.5GM/100ML**	**N18522 001**
				FEB 19, 1982
		@	1.5GM/100ML	N18522 001
				FEB 19, 1982

GRANISETRON HYDROCHLORIDE

TABLET; ORAL

		KYTRIL		
	+	SMITHKLINE BEECHAM	EQ 1MG BASE	N20305 001
				MAR 16, 1995

GUANABENZ ACETATE

TABLET; ORAL

		GUANABENZ ACETATE		
	AB	ZENITH LABS	**EQ 4MG BASE**	**N74149 001**
				APR 07, 1995
			EQ 8MG BASE	N74149 002
				APR 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

		TENEX		
		ROBINS AH	1MG	N19032 001
				OCT 27, 1986
	+		2MG	N19032 002
				NOV 07, 1988
	@		3MG	N19032 003
				NOV 07, 1988
			EQ 1MG BASE	N19032 001
				OCT 27, 1986
	+		EQ 2MG BASE	N19032 002
				NOV 07, 1988
	@		EQ 3MG BASE	N19032 003
				NOV 07, 1988

HALCINONIDE

CREAM; TOPICAL

	HALOG			
AT	* WESTWOOD SQUIBB	0.1%		N17556 001
	+	0.1%		N17556 001
	HALOG-E			
AT	WESTWOOD SQUIBB	0.1%		N18234 001
		0.1%		N18234 001

HEPARIN CALCIUM

INJECTABLE; INJECTION

	CALCIPARINE			
	* CHOAY	25,000 UNITS/ML		N18237 001
	@ SANOFI WINTHROP	25,000 UNITS/ML		N18237 001

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN LOCK FLUSH			
AP	SANOFI WINTHROP	10 UNITS/ML		N40082 001 FEB 28, 1995
AP		100 UNITS/ML		N40082 002 FEB 28, 1995
	HEPARIN SODIUM			
AP	* ABBOTT	2,500 UNITS/ML		N05264 014 APR 07, 1986
	*	2,000 UNITS/ML		N05264 013 APR 07, 1986
AP	ELKINS SINN	10,000 UNITS/ML		N17037 013 APR 07, 1986
AP		5,000 UNITS/0.5ML		N17037 013 APR 07, 1986
AP	PHARMA SERVE NY	1,000 UNITS/ML		N86129 001
AP	WYETH AYERST	2,500 UNITS/ML		N17007 007
AP	+	2,500 UNITS/ML		N17007 007
	HEPARIN SODIUM 1000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	200 UNITS/100ML		N19130 001 DEC 31, 1984
	@	200 UNITS/100ML		N19130 001 DEC 31, 1984
	HEPARIN SODIUM 2000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	200 UNITS/100ML	>_DLT_>	N19130 003 DEC 31, 1984 >_DLT_>
	@ MCGAW	200 UNITS/100ML		N19130 003 DEC 31, 1984
	HEPARIN SODIUM 5000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	1,000 UNITS/100ML		N19130 002 DEC 31, 1984
	@	1,000 UNITS/100ML		N19130 002 DEC 31, 1984
	HEPARIN SODIUM PRESERVATIVE FREE			
AP	+ ABBOTT	2,500 UNITS/ML		N05264 014 APR 07, 1986
	+	2,000 UNITS/ML		N05264 013 APR 07, 1986
AP	FUJISAWA	1,000 UNITS/ML		N17029 010 APR 28, 1986
AP	+	1,000 UNITS/ML		N17029 010 APR 28, 1986
AP	PHARMA SERVE NY	1,000 UNITS/ML		N86129 001
AP	STERLING WINTHROP	10,000 UNITS/ML		N89522 001 MAY 04, 1987
AP	+	10,000 UNITS/ML		N89522 001 MAY 04, 1987
	LIQUAEMIN LOCK FLUSH			
AP	ORGANON	100 UNITS/ML		N00552 007
	@	100 UNITS/ML		N00552 007
	LIQUAEMIN SODIUM			
AP	ORGANON	1,000 UNITS/ML		N00552 004
AP		5,000 UNITS/ML		N00552 003
AP		10,000 UNITS/ML		N00552 005
	@	1,000 UNITS/ML		N00552 004
	@	5,000 UNITS/ML		N00552 003
	@	10,000 UNITS/ML		N00552 005

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

	DRALZINE			
AA	LEMMON	25MG		N84301 001
	@	25MG		N84301 001
	HYDRALAZINE HCL			
AA	HALSEY	50MG		N89222 001 JAN 22, 1986

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HCL
>ADD< @ HALSEY 50MG N89222 001
>ADD< JAN 22, 1986

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
APRESOLINE-ESIDRIX
\+ CIBA 25MG;15MG N12026 002
@ 25MG;15MG N12026 002

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE
AB ASCOT **50MG** **N87540 001**
FEB 03, 1982
@ 50MG N87540 001
FEB 03, 1982

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
HYZAAR
\+ MERCK 12.5MG;50MG N20387 001
APR 28, 1995

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL
LOPRESSOR HCT
CIBA 25MG;50MG N18303 001
DEC 31, 1984
25MG;100MG N18303 002
DEC 31, 1984
\+ 50MG;100MG N18303 003
DEC 31, 1984

LOPRESSOR HCT 100/25
CIBA 25MG;100MG N18303 002
DEC 31, 1984

LOPRESSOR HCT 100/50
\+ CIBA 50MG;100MG N18303 003
DEC 31, 1984

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL
LOPRESSOR HCT 50/25
CIBA 25MG;50MG N18303 001
DEC 31, 1984

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
AB ZENITH LABS **25MG;50MG** **N74259 001**
MAR 30, 1995

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE
AT CLAY PARK **0.5%** **N84970 002**
AT **1%** **N85026 001**
@ 0.5% N84970 002
@ 1% N85026 001

ENEMA; RECTAL
CORTENEMA
AT **+** **100MG/60ML** **N16199 001**
\+ SOLVAY 100MG/60ML N16199 001
HYDROCORTISONE
AT COPLEY PHARM **100MG/60ML** **N74171 001**
MAY 27, 1994
@ 100MG/60ML N74171 001
MAY 27, 1994

LOTION; TOPICAL
HYDROCORTISONE
>DLT< **AT** CLAY PARK **0.5%** **N85662 001**
>ADD< @ 0.5% N85662 001

OINTMENT; TOPICAL
HYDROCORTISONE
CLAY PARK 0.5% N84969 003
>DLT<
>ADD< @ 0.5% N84969 003

HYDROCORTISONE ACETATE

AEROSOL; RECTAL
CORTIFOAM
> DLT > + REED AND CARNRICK 10% N17351 001 FEB 10, 1982
> DLT >
> ADD > + SPKU 10% N17351 001 FEB 10, 1982
> ADD >

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL
AP PHARMAFAIR 50MG/ML N88881 001 FEB 14, 1986
@ 50MG/ML N88881 001 FEB 14, 1986
AP STERIS 25MG/ML N87274 001 > DLT >
AP 50MG/ML N87274 002 > DLT >
@ 25MG/ML N87274 001 > DLT >
@ 50MG/ML N87274 002 > DLT >
> ADD >
> ADD >
> ADD >
> ADD >

SYRUP; ORAL
HYDROXYZINE HCL
AA BARRE 10MG/5ML N88785 001 FEB 03, 1988
@ 10MG/5ML N88785 001 FEB 03, 1988

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S MOTRIN
BX + MCNEIL CONS PRODS 100MG/5ML N19842 001 SEP 19, 1989

PEDIA PROFEN
BX + MCNEIL CONS PRODS 100MG/5ML N19842 001 SEP 19, 1989

SUSPENSION/DROPS; ORAL
MOTRIN
+ MCNEIL CONS PRODS 40MG/ML N20476 001 MAY 25, 1995 > ADD > > ADD >

IOPROMIDE

INJECTABLE; INJECTION
ULTRAVIST
+ BERLEX EQ 150MG IODINE/ML N20220 004 MAY 10, 1995
+ EQ 240MG IODINE/ML N20220 003 MAY 10, 1995
+ EQ 300MG IODINE/ML N20220 002 MAY 10, 1995
+ EQ 370MG IODINE/ML N20220 001 MAY 10, 1995

IOTROLAN

INJECTABLE; INTRATHECAL
OSMOVIST
@ BERLEX EQ 190MG IODINE/ML N19580 001 DEC 07, 1989
@ EQ 240MG IODINE/ML N19580 002 DEC 07, 1989
EQ 190MG IODINE/ML N19580 001 DEC 07, 1989
EQ 240MG IODINE/ML N19580 002 DEC 07, 1989

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL S/F
AN + DEY 1% N89252 001 SEP 15, 1986
@ 1% N89252 001 SEP 15, 1986

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE
AN MARSAM 99.9% N74393 001 MAY 12, 1995
AN RHONE POULENC 99.9% N74502 001 JUN 27, 1995

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

		DILATRATE-SR			
> DLT >	BC	REED AND CARNRICK	40MG	N19790 001	
> DLT >				SEP 02, 1988	
> ADD >	BC	SPKU	40MG	N19790 001	
> ADD >				SEP 02, 1988	

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

	IMDUR			
	@ SCHERING	30MG	N20225 001	
			AUG 12, 1993	
	+	60MG	N20225 002	
			AUG 12, 1993	
	+	120MG	N20225 003	
			MAR 30, 1995	
	@ SCHERING PLOUGH	30MG	N20225 001	
			AUG 12, 1993	
	+	60MG	N20225 002	
			AUG 12, 1993	

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KANAMYCIN				
AP	ELKINS SINN	EQ 75MG BASE/2ML	N62324 001		
AP		EQ 500MG BASE/2ML	N62324 002		
AP		EQ 1GM BASE/3ML	N62324 003		
	@	EQ 75MG BASE/2ML	N62324 001	> ADD >	
	@	EQ 500MG BASE/2ML	N62324 002	> ADD >	
	@	EQ 1GM BASE/3ML	N62324 003	> ADD >	

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

	ORUVAIL			
	+ WYETH AYERST	100MG	N19816 003	
			FEB 08, 1995	
	+	150MG	N19816 002	
			FEB 08, 1995	

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL

	PREVACID			
	TAP HOLDINGS	15MG	N20406 001	
			MAY 10, 1995	
	+	30MG	N20406 002	
			MAY 10, 1995	

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

	LEUCOVORIN CALCIUM			
	+ CETUS BEN VENUE	EQ 200MG BASE/VIAL	N40056 001	
			MAY 23, 1995	

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

	LUPRON			
	+ TAP HOLDINGS	1MG/0.2ML	N19010 001	
			APR 09, 1985	
	+ TAP PHARMS	5MG/ML	N19010 001	
			APR 09, 1985	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL				
AP	SANOFI WINTHROP	1%	N40013 001		
			JUN 23, 1995	> ADD >	
AP		2%	N40078 001		
			JUN 23, 1995		

LINDANE

LOTION; TOPICAL

	SCABENE			
AT	STIEFEL	1%	N86769 001	
	@	1%	N86769 001	

SHAMPOO; TOPICAL

	SCABENE			
AT	STIEFEL	1%	N87940 001	
			APR 08, 1983	

LINDANE

SHAMPOO; TOPICAL

	SCABENE			
	@ STIEFEL	1%		N87940 001 APR 08, 1983

LISINOPRIL

TABLET; ORAL

	PRINIVIL			
AB	MERCK	2.5MG		N19558 006 JAN 28, 1994
		2.5MG		N19558 006 JAN 28, 1994
	ZESTRIL			
AB	ZENECA	2.5MG		N19777 005 APR 29, 1993
	@	2.5MG		N19777 005 APR 29, 1993

LITHIUM CARBONATE

TABLET; ORAL

	LITHOTABS			
AB	SOLVAY	300MG		N16980 001
AB	+	300MG		N16980 001

LOSARTAN POTASSIUM

TABLET; ORAL

	COZAAR			
	MERCK	25MG		N20386 001 APR 14, 1995
	+	50MG		N20386 002 APR 14, 1995

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

	PHYSIOLYTE IN PLASTIC CONTAINER			
AT	MCGAW	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML		N19024 001 JUN 08, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

	PHYSIOLYTE IN PLASTIC CONTAINER			
	MCGAW	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML		N19024 001 JUN 08, 1984
	PHYSIOSOL IN PLASTIC CONTAINER			
AT	ABBOTT	30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML		N17637 002 JUL 08, 1982
		30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML		N17637 002 JUL 08, 1982
	SYNOVALYTE IN PLASTIC CONTAINER			
AT	BAXTER	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML		N19326 001 JAN 25, 1985
	@	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML		N19326 001 JAN 25, 1985

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 10%			
AP	ABBOTT	10GM/100ML		N16269 002
	@	10GM/100ML		N16269 002
	MANNITOL 15%			
AP	ABBOTT	15GM/100ML		N16269 003
	@	15GM/100ML		N16269 003
	MANNITOL 20%			
AP	ABBOTT	20GM/100ML		N16269 004
	@	20GM/100ML		N16269 004
	MANNITOL 25%			
AP	ABBOTT	12.5GM/50ML		N16269 005
AP		12.5GM/50ML		N16269 006 AUG 25, 1994
	@	12.5GM/50ML		N16269 005
	MANNITOL 5%			
AP	ABBOTT	5GM/100ML		N16269 001
	@	5GM/100ML		N16269 001

MASOPROCOL

CREAM; TOPICAL
ACTINEX

> DLT >		+	BLOCK DRUG	10%	N19940 001
> DLT >					SEP 04, 1992
> ADD >		+	SPKU	10%	N19940 001
> ADD >					SEP 04, 1992

MEBENDAZOLE

TABLET, CHEWABLE; ORAL
MEBENDAZOLE

AB		COPLEY PHARM	100MG	N73580 001
				JAN 04, 1995

VERMOX

AB	+	JANSSEN	100MG	N17481 001

MEGESTROL ACETATE

TABLET; ORAL
MEGACE

AB		BRISTOL MYERS SQUIBB	20MG	N16979 001
AB	+		40MG	N16979 002
AB		MEAD JOHNSON	20MG	N16979 001
AB	+		40MG	N16979 002

METAPROTERENOL SULFATE

SYRUP; ORAL
ALUPENT

> DLT >	AA		BOEHRINGER INGELHEIM	10MG/5ML	N17571 001
> ADD >	AA	+		10MG/5ML	N17571 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

	BRISTOL MYERS SQUIBB	500MG	N20357 001
			DEC 29, 1994
+		850MG	N20357 002
			DEC 29, 1994
	LIPHA	500MG	N20357 001
			DEC 29, 1994

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

+	LIPHA	850MG	N20357 002
			DEC 29, 1994

METHADONE HYDROCHLORIDE

POWDER; FOR RX COMPOUNDING
METHADONE HCL

MALLINCKRODT	50GM/BOT	N06383 002
	100GM/BOT	N06383 003
	500GM/BOT	N06383 004

TABLET, DISPERSIBLE; ORAL
METHADONE HCL

AA	ROXANE	40MG	N74081 001
			APR 28, 1995

METHOTRIMEPRAZINE

INJECTABLE; INJECTION
LEVOPROME

+	IMMUNEX	20MG/ML	N15865 001
+	LEDERLE	20MG/ML	N15865 001

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

AP	DUPONT MERCK	50MG/ML	N70691 001
			JUN 19, 1987
AP		50MG/ML	N70849 001
			JUN 19, 1987
AP	FAULDING	50MG/ML	N70691 001
			JUN 19, 1987
AP		50MG/ML	N70849 001
			JUN 19, 1987

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	DUPONT MERCK	EQ 10MG BASE/2ML	N70847 001
			NOV 07, 1988

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	DUPONT MERCK	EQ 10MG BASE/2ML	N71291 001 MAR 03, 1989
AP	FAULDING	EQ 10MG BASE/2ML	N70847 001 NOV 07, 1988
AP		EQ 10MG BASE/2ML	N71291 001 MAR 03, 1989

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

AB	LEMMON	50MG	N74141 001 JAN 31, 1995
AB		100MG	N74141 002 JAN 31, 1995
AB	PAR PHARM	50MG	N74453 001 APR 27, 1995
AB		100MG	N74453 002 APR 27, 1995

METRONIDAZOLE

CAPSULE; ORAL
FLAGYL

+	SEARLE	375MG	N20334 001 MAY 03, 1995

METYRAPONE

TABLET; ORAL
METOPIRONE

+	CIBA	250MG	N12911 001
@		250MG	N12911 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	NOVOPHARM	150MG	N74377 001 MAY 16, 1995

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	NOVOPHARM	200MG	N74377 002 MAY 16, 1995
AB		250MG	N74377 003 MAY 16, 1995

MEXITIL

AB	BOEHRINGER INGELHEIM	150MG	N18873 002 DEC 30, 1985
AB		200MG	N18873 003 DEC 30, 1985
AB	+	250MG	N18873 004 DEC 30, 1985

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB	ABLE	200MG	N73508 001 NOV 19, 1993
AB	NMC	200MG	N73508 001 NOV 19, 1993

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	CETUS BEN VENUE	5MG/VIAL	N64117 001 APR 19, 1995
		20MG/VIAL	N64117 002 APR 19, 1995

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
UNIVASC

	SPKU	7.5MG	N20312 001 APR 19, 1995
	+	15MG	N20312 002 APR 19, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

		CELLCEPT	250MG	N50722 001	MAY 03, 1995
		+ SYNTEX			

NAFCILLIN SODIUM

INJECTABLE; INJECTION

> DLT >		NAFCIL			
> DLT >	AP	APOTHECON	EQ 500MG BASE/VIAL	N61984 001	
> DLT >	AP		EQ 500MG BASE/VIAL	N62527 001	
> DLT >				AUG 02, 1984	
> DLT >	AP		EQ 1GM BASE/VIAL	N61984 002	
> DLT >	AP		EQ 1GM BASE/VIAL	N62527 002	
> DLT >				AUG 02, 1984	
> DLT >	AP		EQ 1GM BASE/VIAL	N62732 001	
> DLT >				DEC 23, 1986	
> DLT >	AP		EQ 2GM BASE/VIAL	N61984 003	
> DLT >	AP		EQ 2GM BASE/VIAL	N62527 003	
> DLT >				AUG 02, 1984	
> DLT >	AP		EQ 2GM BASE/VIAL	N62732 002	
> DLT >				DEC 23, 1986	
> DLT >	AP		EQ 4GM BASE/VIAL	N61984 005	
> DLT >	AP		EQ 10GM BASE/VIAL	N62527 004	
> DLT >				AUG 02, 1984	
> ADD >		NAFCILLIN SODIUM			
> ADD >	AP	APOTHECON	EQ 500MG BASE/VIAL	N61984 001	
> ADD >	AP		EQ 500MG BASE/VIAL	N62527 001	
> ADD >				AUG 02, 1984	
> ADD >	AP		EQ 1GM BASE/VIAL	N61984 002	
> ADD >	AP		EQ 1GM BASE/VIAL	N62527 002	
> ADD >				AUG 02, 1984	
> ADD >	AP		EQ 1GM BASE/VIAL	N62732 001	
> ADD >				DEC 23, 1986	
> ADD >	AP		EQ 2GM BASE/VIAL	N61984 003	
> ADD >	AP		EQ 2GM BASE/VIAL	N62527 003	
> ADD >				AUG 02, 1984	
> ADD >	AP		EQ 2GM BASE/VIAL	N62732 002	
> ADD >				DEC 23, 1986	
> ADD >	AP		EQ 4GM BASE/VIAL	N61984 005	
> ADD >	AP		EQ 10GM BASE/VIAL	N62527 004	
> ADD >				AUG 02, 1984	

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

	REVEX			
	OHMEDA	EQ 0.1MG BASE/ML	N20459 001	APR 17, 1995
	+	EQ 1MG BASE/ML	N20459 002	APR 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

		NALOXONE HCL			
> DLT >	AP	FUJISAWA	0.02MG/ML	N70648 001	
> DLT >				NOV 17, 1986	
> DLT >	AP		0.4MG/ML	N70649 001	
> DLT >				NOV 17, 1986	
> ADD >		@	0.02MG/ML	N70648 001	
> ADD >				NOV 17, 1986	
> ADD >		@	0.4MG/ML	N70649 001	
> ADD >				NOV 17, 1986	

NAPROXEN

TABLET; ORAL

		NAPROXEN			
AB		CHELSEA LABS	250MG	N74457 001	
AB			375MG	MAY 31, 1995	
AB			500MG	N74457 002	
AB		DANBURY PHARMA	250MG	MAY 31, 1995	
AB			375MG	N74457 003	
AB			500MG	MAY 31, 1995	
AB		MOVA	250MG	N74163 001	
AB			375MG	FEB 10, 1995	
AB			500MG	N74163 002	
AB		ZENITH LABS	250MG	FEB 10, 1995	
				N74163 003	
				FEB 10, 1995	
				N74410 001	
				APR 28, 1995	
				N74410 002	
				APR 28, 1995	
				N74410 003	
				APR 28, 1995	
				N74111 001	
				FEB 28, 1995	

NAPROXEN

TABLET; ORAL
NAPROXEN

AB		ZENITH LABS	375MG	N74111 002 FEB 28, 1995
AB			500MG	N74111 003 FEB 28, 1995

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB		CHELSEA LABS	EQ 250MG BASE	N74455 001 MAY 31, 1995
AB			EQ 500MG BASE	N74455 002 MAY 31, 1995
AB		PUREPAC PHARM	EQ 250MG BASE	N74319 001 MAR 20, 1995
AB			EQ 500MG BASE	N74319 002 MAR 20, 1995
AB		ZENITH LABS	EQ 250MG BASE	N74230 001 MAR 14, 1995
AB			EQ 500MG BASE	N74230 002 MAR 14, 1995

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

AA		BIOCRAFT	EQ 350MG BASE	N60304 001
			EQ 350MG BASE	N60304 001
AA		LILLY	EQ 350MG BASE	N60385 001
	@		EQ 350MG BASE	N60385 001

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
HABITROL

BC	+	BASEL PHARMS	7MG/24HR	N20076 001 NOV 27, 1991
BC	+		14MG/24HR	N20076 002 NOV 27, 1991
BC	+		21MG/24HR	N20076 003 NOV 27, 1991

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
HABITROL

BC	+	CIBA	7MG/24HR	N20076 001 NOV 27, 1991
BC	+		14MG/24HR	N20076 002 NOV 27, 1991
BC	+		21MG/24HR	N20076 003 NOV 27, 1991

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICORETTE

	+	MERRELL DOW	EQ 2MG BASE	N18612 001 JAN 13, 1984
	+	SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 001 JAN 13, 1984

NICORETTE DS

	+	MERRELL DOW	EQ 4MG BASE	N20066 001 JUN 08, 1992
	+	SMITHKLINE BEECHAM	EQ 4MG BASE	N20066 001 JUN 08, 1992

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
NISOCOR

	+	MILES	10MG	N20356 001 FEB 02, 1995
	+		20MG	N20356 002 FEB 02, 1995
	+		30MG	N20356 003 FEB 02, 1995
	+		40MG	N20356 004 FEB 02, 1995

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN

AB		GENEVA PHARMS	25MG	N74336 001 JAN 25, 1995
AB			50MG	N74336 002 JAN 25, 1995

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN

AB	GENEVA PHARMS	100MG	N74336 003	JAN 25, 1995

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
NITRO-DUR

	+ KEY PHARMS	0.1MG/HR	N20145 001	APR 04, 1995
	+	0.2MG/HR	N20145 002	APR 04, 1995
	+	0.3MG/HR	N20145 003	APR 04, 1995
	+	0.4MG/HR	N20145 004	APR 04, 1995
	+	0.6MG/HR	N20145 005	APR 04, 1995
	+	0.8MG/HR	N20145 006	APR 04, 1995

INJECTABLE; INJECTION
NITROGLYCERIN

> DLT > AP	FUJISAWA	5MG/ML	N70077 001	DEC 13, 1985
> DLT >				
> ADD >	@	5MG/ML	N70077 001	DEC 13, 1985
> ADD >				

NITROSTAT

AP	PARKE DAVIS	5MG/ML	N18588 002	DEC 23, 1983
	+	0.8MG/ML	N18588 001	
	@	0.8MG/ML	N18588 001	
	@	5MG/ML	N18588 002	DEC 23, 1983

TRIDIL

AP	DUPONT MERCK	5MG/ML	N18537 001	
	+	0.5MG/ML	N18537 002	JUN 16, 1983
AP	FAULDING	5MG/ML	N18537 001	
	+	0.5MG/ML	N18537 002	JUN 16, 1983

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL

AB	LEMMON	EQ 10MG BASE	N74132 001	MAR 27, 1995
AB		EQ 25MG BASE	N74132 002	MAR 27, 1995
AB		EQ 50MG BASE	N74132 003	MAR 27, 1995
AB		EQ 75MG BASE	N74132 004	MAR 27, 1995

NYSTATIN

TABLET; ORAL
MYCOSTATIN

AA	+ APOTHECON	500,000 UNITS	N60574 001	
AA	+ SQUIBB	500,000 UNITS	N60574 001	

TABLET; VAGINAL
NYSTATIN

AT	LEMMON	100,000 UNITS	N62502 001	DEC 23, 1983
	@	100,000 UNITS	N62502 001	DEC 23, 1983

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	PHARMAPAIR	100,000 UNITS/GM;0.1%	N62656 001	JUL 30, 1986
	@	100,000 UNITS/GM;0.1%	N62656 001	JUL 30, 1986

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ZOFRAN IN PLASTIC CONTAINER

	+ GLAXO	EQ 0.64MG BASE/ML	N20403 001	JAN 31, 1995

OXACILLIN SODIUM

CAPSULE; ORAL

>_ADD_>		OXACILLIN SODIUM			
>_ADD_>	AB	APOTHECON	EQ 250MG BASE		N61450 002
>_ADD_>	AB	+	EQ 500MG BASE		N61450 001
>_DLT_>		PROSTAPHLIN			
>_DLT_>	AB	APOTHECON	EQ 250MG BASE		N61450 002
>_DLT_>	AB	+	EQ 500MG BASE		N61450 001

POWDER FOR RECONSTITUTION; ORAL

>_ADD_>		OXACILLIN SODIUM			
>_ADD_>	AA	APOTHECON	EQ 250MG BASE/5ML		N61457 001
>_DLT_>		PROSTAPHLIN			
>_DLT_>	AA	APOTHECON	EQ 250MG BASE/5ML		N61457 001

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL

		DARICON			
	+	PFIZER	10MG		N11612 001
	@		10MG		N11612 001

PENBUTOLOL SULFATE

TABLET; ORAL

		LEVATOL			
>_DLT_>	@	REED AND CARNRICK	10MG		N18976 001
>_DLT_>					DEC 30, 1987
>_DLT_>	+		20MG		N18976 004
>_DLT_>					JAN 05, 1989
>_ADD_>	@	SPKU	10MG		N18976 001
>_ADD_>					DEC 30, 1987
>_ADD_>	+		20MG		N18976 004
>_ADD_>					JAN 05, 1989

PENICILLAMINE

TABLET; ORAL

		DEPEN			
	+	WALLACE	250MG		N19854 001
		DEPEN 250			
	+	WALLACE	250MG		N19854 001

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

		PENICILLIN G POTASSIUM			
	@	CONSOLIDATED PHARM	500,000 UNITS/VIAL		N60806 001
	@		1,000,000 UNITS/VIAL		N60806 002
	@		5,000,000 UNITS/VIAL		N60806 003
	@		10,000,000 UNITS/VIAL		N60806 004
	@	COPANOS	500,000 UNITS/VIAL		N60806 001
	@		1,000,000 UNITS/VIAL		N60806 002
	@		5,000,000 UNITS/VIAL		N60806 003
	@		10,000,000 UNITS/VIAL		N60806 004
AP	+	LILLY	1,000,000 UNITS/VIAL		N60384 002
AP	+		5,000,000 UNITS/VIAL		N60384 001
AP	+		20,000,000 UNITS/VIAL		N60384 005
AP			20,000,000 UNITS/VIAL		N60601 001
	+		200,000 UNITS/VIAL		N60384 004
	+		500,000 UNITS/VIAL		N60384 003
	@		200,000 UNITS/VIAL		N60384 004
	@		500,000 UNITS/VIAL		N60384 003
	@		1,000,000 UNITS/VIAL		N60384 002
	@		5,000,000 UNITS/VIAL		N60384 001
	@		20,000,000 UNITS/VIAL		N60384 005
	@		20,000,000 UNITS/VIAL		N60601 001
		PFIZERPEN			
AP		PFIZER	1,000,000 UNITS/VIAL		N60657 001
AP	+		1,000,000 UNITS/VIAL		N60657 001
AP			5,000,000 UNITS/VIAL		N60657 002
AP	+		5,000,000 UNITS/VIAL		N60657 002
AP			20,000,000 UNITS/VIAL		N60657 003
AP	+		20,000,000 UNITS/VIAL		N60657 003

TABLET; ORAL

		PENICILLIN G POTASSIUM			
AB		DISTA	250,000 UNITS		N60403 001
	@	LILLY	250,000 UNITS		N60403 001

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

		PENICILLIN G PROCAINE			
	@	CONSOLIDATED PHARM	300,000 UNITS/ML		N60800 001
	@		600,000 UNITS/1.2ML		N60800 002
	@	COPANOS	300,000 UNITS/ML		N60800 001
	@		600,000 UNITS/1.2ML		N60800 002

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

		PENICILLIN V POTASSIUM		
AA		CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61529 001
AA			EQ 250MG BASE/5ML	N61529 002
AA		COPANOS	EQ 125MG BASE/5ML	N61529 001
AA			EQ 250MG BASE/5ML	N61529 002

TABLET; ORAL

		BETAPEN-VK		
> DLT >	AB	APOTHECON	EQ 250MG BASE	N61411 001
> DLT >	AB		EQ 500MG BASE	N61411 002
		PENICILLIN V POTASSIUM		
	AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61528 001
	AB		EQ 500MG BASE	N61528 002
	AB	COPANOS	EQ 250MG BASE	N61528 001
	AB		EQ 500MG BASE	N61528 002
> ADD >		**VEETIDS**		
> ADD >	AB	APOTHECON	EQ 250MG BASE	N61411 001
> ADD >	AB		EQ 500MG BASE	N61411 002

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

		PENTACARINAT		
AP		ARMOUR	300MG/VIAL	N73447 001 APR 28, 1994
AP		RHONE POULENC RORER	300MG/VIAL	N73447 001 APR 28, 1994

PERINDOPRIL ERBUMINE

TABLET; ORAL

	ACEON		
	AMARIC	2MG	N20184 001 DEC 30, 1993
		4MG	N20184 002 DEC 30, 1993
+		8MG	N20184 003 DEC 30, 1993
	JOHNSON RW	2MG	N20184 001 DEC 30, 1993
		4MG	N20184 002 DEC 30, 1993
+		8MG	N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

	MELFIAT-105		
	@ NUMARK	105MG	N87487 001 OCT 13, 1982
	@ SOLVAY	105MG	N87487 001 OCT 13, 1982
	SPRX-105		
	@ NUMARK	105MG	N88024 001 DEC 22, 1982
	@ SOLVAY	105MG	N88024 001 DEC 22, 1982

TABLET; ORAL

	MELFIAT		
	@ NUMARK	35MG	N83790 002
	@ SOLVAY	35MG	N83790 002
	PHENDIMETRAZINE TARTRATE		
	@ NUMARK	35MG	N83790 001
	@ SOLVAY	35MG	N83790 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

		PHENTERMINE HCL		
AA		LEMMON	30MG	N87777 001 NOV 01, 1985
		@	30MG	N87777 001 NOV 01, 1985

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

	IONAMIN		
	FISONS	EQ 15MG BASE	N11613 004
+		EQ 30MG BASE	N11613 002
	IONAMIN-15		
	FISONS	EQ 15MG BASE	N11613 004
	IONAMIN-30		
+	FISONS	EQ 30MG BASE	N11613 002

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	ROYCE LABS	5MG	N74437 001	FEB 27, 1995
AB		10MG	N74437 002	FEB 27, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

POWDER FOR RECONSTITUTION; ORAL
NULYTELY-FLAVORED

	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT	N19797 002 NOV 18, 1994

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
GOLYTELY

AA	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N19011 002 JUN 02, 1992

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
MINIZIDE

	PFIZER	0.5MG;1MG	N17986 001
		0.5MG;2MG	N17986 002
+		0.5MG;5MG	N17986 003
		0.5MG;EQ 1MG BASE	N17986 001
		0.5MG;EQ 2MG BASE	N17986 002
+		0.5MG;EQ 5MG BASE	N17986 003

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
KAON CL

	SAVAGE LABS	6.7MEQ	N17046 001
@		6.7MEQ	N17046 001

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
KAON CL-10

BC	SAVAGE LABS	10MEQ	N17046 002
@		10MEQ	N17046 002

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDELTRASOL

AP	MERCK SHARP DOHME	EQ 20MG PHOSPHATE/ML	N11583 002
+		EQ 20MG PHOSPHATE/ML	N11583 002

PREDNISOLONE SODIUM PHOSPHATE

AP	STERIS	EQ 20MG PHOSPHATE/ML	N80517 001
@		EQ 20MG PHOSPHATE/ML	N80517 001

PROCAINAMIDE HYDROCHLORIDE

TABLET; ORAL
PRONESTYL

	APOTHECON	250MG	N17371 001
		375MG	N17371 002
+		500MG	N17371 003
	SQUIBB	250MG	N17371 001
		375MG	N17371 002
+		500MG	N17371 003

TABLET, EXTENDED RELEASE; ORAL
PROCAN SR

AB	PARKE DAVIS	250MG	N86468 001
@		250MG	N86468 001
	PRONESTYL-SR		
BC	APOTHECON	500MG	N87361 001
BC	BRISTOL MYERS SQUIBB	500MG	N87361 001

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

AA	DANBURY PHARMA	15MG	N83029 002
@		15MG	N83029 002
AA	GLOBAL PHARMS	15MG	N84541 002
@		15MG	N84541 002
AA	TABLICAPS	15MG	N84428 001
@		15MG	N84428 001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPHTHAINE

AT	+ APOTHECON	0.5%		N08883 001
AT	+ SQUIBB	0.5%		N08883 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	PARKE DAVIS	20MG		N70439 001
				SEP 15, 1986
AB		40MG		N70440 001
				SEP 15, 1986
AB		60MG		N70441 001
				SEP 24, 1986
AB		80MG		N70442 001
				SEP 15, 1986
AB	WARNER CHILCOTT	10MG		N70438 001
				SEP 15, 1986
	@	10MG		N70438 001
				SEP 15, 1986
	@	20MG		N70439 001
				SEP 15, 1986
	@	40MG		N70440 001
				SEP 15, 1986
	@	60MG		N70441 001
				SEP 24, 1986
	@	80MG		N70442 001
				SEP 15, 1986

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

BD	LILLY	50MG		N06213 001
	@	50MG		N06213 001

QUINESTROL

TABLET; ORAL
ESTROVIS

	+ PARKE DAVIS	0.1MG		N16768 002
	@	0.1MG		N16768 002

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM

AA	ZENITH LABS	100MG		N85869 001
	@	100MG		N85869 001

> ADD >

SEVOFLURANE

> ADD >
LIQUID; INHALATION
> ADD >
ULTANE
> ADD >

	ABBOTT	100%		N20478 001
> ADD >				JUN 07, 1995

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER	9MG/ML		N16677 004
				OCT 30, 1985
AP	+	9MG/ML		N16677 004
				OCT 30, 1985

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AT	BAXTER	450MG/100ML		N18497 001
				FEB 19, 1982
	@	450MG/100ML		N18497 001
				FEB 19, 1982

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
BIO-TROPIN

	+ BIO TECH GEN	4.8MG/VIAL		N19774 001
				MAY 25, 1995

NORDITROPIN

	+ NOVO NORDISK	4MG/VIAL		N19721 001
				MAY 08, 1995
	+	8MG/VIAL		N19721 002
				MAY 08, 1995

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

AP	LILLY	EQ 1GM BASE/VIAL	N60107 001	
AP		EQ 5GM BASE/VIAL	N60107 002	
		EQ 1GM BASE/2ML	N60404 001	
	@	EQ 1GM BASE/2ML	N60404 001	
	@	EQ 1GM BASE/VIAL	N60107 001	
	@	EQ 5GM BASE/VIAL	N60107 002	
AP	+ PFIZER	EQ 1GM BASE/VIAL	N60076 001	
AP	+	EQ 5GM BASE/VIAL	N60076 002	
	+	EQ 1GM BASE/VIAL	N60076 001	
	+	EQ 5GM BASE/VIAL	N60076 002	

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCOSTRIN

AP	APOTHECON	20MG/ML	N08847 001
	@	100MG/ML	N08847 003
AP	SQUIBB	20MG/ML	N08847 001
	@	100MG/ML	N08847 003

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA

AB	BARRE	200MG/5ML;40MG/5ML	N72289 001 MAY 23, 1988
	@	200MG/5ML;40MG/5ML	N72289 001 MAY 23, 1988

>_ADD_> SULFUR

>_ADD_> POWDER; TOPICAL
>_ADD_> BENSULFOID
>_ADD_> @ POYTHRESS 33.32% N02918 001

SUMATRIPTAN SUCCINATE

>_ADD_> TABLET; ORAL
>_ADD_> IMITREX
>_ADD_> GLAXO WELLCOME EQ 25MG BASE N20132 002
>_ADD_> JUN 01, 1995

>_ADD_> TABLET; ORAL
>_ADD_> IMITREX
>_ADD_> + GLAXO WELLCOME EQ 50MG BASE N20132 003
>_ADD_> JUN 01, 1995
>_ADD_> @ EQ 100MG BASE N20132 001
>_ADD_> JUN 01, 1995

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNELITE
DUPONT 0.0083-2.7 CI/GENERATOR N17771 001
TECHNETIUM TC 99M GENERATOR
DUPONT 0.0083-2.7 CI/GENERATOR N17771 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

AB	PVT FORM	250MG	N62686 001 JUL 24, 1986
AB		500MG	N62686 002 JUL 24, 1986
	@	250MG	N62686 001 JUL 24, 1986
	@	500MG	N62686 002 JUL 24, 1986

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE

	+ ON SITE	12.7MG/FIBER	N50653 001 MAR 25, 1994
	+ ON SITE ALZA	12.7MG/FIBER	N50653 001 MAR 25, 1994

OINTMENT; OPHTHALMIC
ACHROMYCIN
+ LEDERLE 10MG/GM N50266 001

OINTMENT; OPHTHALMIC, OTIC
ACHROMYCIN
+ LEDERLE 10MG/GM N50266 001

SUSPENSION; ORAL
ACHROMYCIN V

AB	+ LEDERLE	125MG/5ML	N50263 002

TETRACYCLINE HYDROCHLORIDE

SUSPENSION; ORAL

		SUMYCIN		
AB		APOTHECON	125MG/5ML	N60400 001
		TETRACYCLINE HCL		
AB		BARRE	125MG/5ML	N60633 001
AB		MK LABS	125MG/5ML	N60174 001
AB		PUREPAC PHARM	125MG/5ML	N60291 001
		TETRACYN		
AB		PFIPHARMECS	125MG/5ML	N60095 001
		TETRAMED		
AB		ZENITH LABS	125MG/5ML	N61468 001

SYRUP; ORAL

		ACHROMYCIN V		
AB	+	LEDERLE	125MG/5ML	N50263 002
		SUMYCIN		
AB		SQUIBB	125MG/5ML	N60400 001
		TETRACYCLINE HCL		
AB		BARRE	125MG/5ML	N60633 001
AB		MK LABS	125MG/5ML	N60174 001
AB		PUREPAC PHARM	125MG/5ML	N60291 001
		TETRACYN		
AB		PFIPHARMECS	125MG/5ML	N60095 001
		TETRAMED		
AB		ZENITH LABS	125MG/5ML	N61468 001

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

		THEOPHYLLINE		
BC		FAULDING	100MG	N89976 001 JAN 04, 1995
BC			200MG	N89977 001 JAN 04, 1995
BC			300MG	N89932 001 JAN 04, 1995

TABLET, EXTENDED RELEASE; ORAL

		LABID		
BC	+	PROCTER AND GAMBLE	250MG	N87225 001
	@		250MG	N87225 001
		THEOLAIR-SR		
BC		3M	250MG	N86363 002 JUL 16, 1987
			250MG	N86363 002 JUL 16, 1987

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

		THEOPHYLLINE		
AB		INWOOD LABS	450MG	N40034 001 APR 28, 1995
		UNI-DUR		
BC	+	KEY PHARMS	400MG	N89822 001 JAN 04, 1995
	+		600MG	N89823 001 JAN 04, 1995
		UNIPHYL		
BC		PURDUE FREDERICK	400MG	N87571 001 SEP 01, 1982

THIOTEPA

INJECTABLE; INJECTION

		THIOPLEX		
		IMMUNEX	15MG/VIAL	N20058 001 DEC 22, 1994
AP		LEDERLE	15MG/VIAL	N20058 001 DEC 22, 1994
		THIOTEPA		
AP	+	IMMUNEX	15MG/VIAL	N11683 001
	+		15MG/VIAL	N11683 001

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

		BETIMOL		
	+	LEIRAS	EQ 0.25% BASE	N20439 001 MAR 31, 1995
	+		EQ 0.5% BASE	N20439 002 MAR 31, 1995

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

		TIMOLOL MALEATE		
AT		ALCON	EQ 0.25% BASE	N74261 001 APR 28, 1995
AT			EQ 0.5% BASE	N74262 001 APR 28, 1995
		TIMOPTIC		
AT	+	MERCK	EQ 0.25% BASE	N18086 001

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOPTIC
AT + MERCK EQ 0.5% BASE N18086 002

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1
+ BRISTOL MYERS 6.5% N19355 001
DEC 30, 1986
+ BRISTOL MYERS SQUIBB 6.5% N19355 001
DEC 30, 1986

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL
TONOCARD
ASTRA MERCK 400MG N18257 001 >DLT>
NOV 09, 1984 >DLT>
+ 600MG N18257 002 >ADD>
NOV 09, 1984 >ADD>
MERCK SHARP DOHME 400MG N18257 001
NOV 09, 1984
+ 600MG N18257 002
NOV 09, 1984

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
ULTRAM
+ JOHNSON RW 50MG N20281 002
MAR 03, 1995
@ 100MG N20281 001
MAR 03, 1995

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
KENALOG-H
AT APOTHECON 0.1% N86240 001
AT WESTWOOD SQUIBB 0.1% N86240 001

INJECTABLE; INJECTION
KENALOG-10
+ APOTHECON 10MG/ML N12041 001

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION
KENALOG-10
+ WESTWOOD SQUIBB 10MG/ML N12041 001
KENALOG-40
BP APOTHECON 40MG/ML N14901 001
BP WESTWOOD SQUIBB 40MG/ML N14901 001

LOTION; TOPICAL
KENALOG
AT APOTHECON 0.025% N84343 001
AT + 0.1% N84343 002
@ 0.025% N11602 003
@ 0.1% N11602 001
AT WESTWOOD SQUIBB 0.025% N84343 001
AT + 0.1% N84343 002
@ 0.025% N11602 003
@ 0.1% N11602 001
TRIAMCINOLONE ACETONIDE
AT BARRE 0.025% N87191 001
SEP 08, 1982
@ 0.025% N87191 001
SEP 08, 1982

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE IN ABSORBASE
+ CAROLINA MEDCL 0.05% N89595 001
MAR 23, 1995

PASTE; DENTAL
KENALOG IN ORABASE
AT + APOTHECON 0.1% N12097 001
AT + SQUIBB 0.1% N12097 001

TRICHLORMETHIAZIDE

TABLET; ORAL
NAQUA
BP SCHERING 2MG N12265 001
@ 2MG N12265 001

TRILOSTANE

CAPSULE; ORAL
MODRASTANE
SANOFI WINTHROP 30MG N18719 002
DEC 31, 1984

TRILOSTANE

CAPSULE; ORAL
MODRASTANE
+ SANOFI WINTHROP — 60MG — N18719 001 DEC 31, 1984
@ — 30MG — N18719 002 DEC 31, 1984
@ — 60MG — N18719 001 DEC 31, 1984

> ADD > TRIMETHOPRIM HYDROCHLORIDE

> ADD > SOLUTION; ORAL
> ADD > PRIMSOL
> ADD > ASCENT — EQ 25MG BASE/5ML — N74374 001 JUN 23, 1995
> ADD >

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
AP + APOTHECON — 3MG/ML — N05657 001
AP + SQUIBB — 3MG/ML — N05657 001

> ADD > VALACYCLOVIR HYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > VALTREX
> ADD > + BURROUGHS WELLCOME — EQ 500MG BASE — N20487 001 JUN 23, 1995
> ADD >
> ADD > @ — EQ 1GM BASE — N20487 002 JUN 23, 1995
> ADD >

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID
AA HIGH TECH PHARMA — 250MG/5ML — N74060 001 JAN 13, 1995

VANCOMYCIN HYDROCHLORIDE

POWDER FOR RECONSTITUTION; ORAL
VANCOCIN HCL
AB + LILLY — EQ 500MG BASE/6ML — N61667 001
+ — EQ 500MG BASE/6ML — N61667 001
VANCOLED
AB LEDERLE — EQ 500MG BASE/6ML — N63321 003 OCT 15, 1993
@ — EQ 500MG BASE/6ML — N63321 003 OCT 15, 1993

VITAMIN A

CAPSULE; ORAL
VITAMIN A
AA BANNER PHARMACAPS — 50,000 USP UNITS — N83973 001
@ — 50,000 USP UNITS — N83973 001

VITAMIN A PALMITATE

CAPSULE; ORAL
VITAMIN A
AA BANNER PHARMACAPS — EQ 50,000 UNITS BASE — N80702 001
@ — EQ 50,000 UNITS BASE — N80702 001
VITAMIN A PALMITATE
AA BANNER PHARMACAPS — EQ 50,000 UNITS BASE — N83948 001
@ — EQ 50,000 UNITS BASE — N83948 001

WARFARIN SODIUM

INJECTABLE; INJECTION
COUMADIN
+ DUPONT MERCK — 5MG/VIAL — N09218 024 FEB 07, 1995

ACETAMINOPHEN

SUPPOSITORY; RECTAL
ACETAMINOPHEN
ABLE 120MG N73106 001 FEB 27, 1995
325MG N73107 001 FEB 27, 1995
650MG N73108 001 FEB 27, 1995

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
VASOCON-A
+ CIBA 0.5%;0.05% N18746 002 JUL 11, 1994

>ADD< CIMETIDINE

>ADD< TABLET; ORAL
>ADD< TAGAMET HB
>ADD< + SMITHKLINE BEECHAM 100MG N20238 001 JUN 19, 1995

FAMOTIDINE

TABLET; ORAL
PEPCID AC
+ MERCK 10MG N20325 001 APR 28, 1995

IBUPROFEN

CAPSULE; ORAL
MIDOL
+ WINTHROP 200MG N70626 001 SEP 02, 1987
200MG N71002 001 SEP 02, 1987
@ 200MG N70626 001 SEP 02, 1987
@ 200MG N71002 001 SEP 02, 1987

IBUPROFEN

CAPSULE; ORAL
PROVEL
+ SANDOZ 200MG N20402 001 APR 20, 1995

>ADD< SUSPENSION; ORAL
>ADD< CHILDREN'S MOTRIN
>ADD< + MCNEIL CONS PRODS 100MG/5ML N20516 001 JUN 16, 1995

TABLET; ORAL
MIDOL
WINTHROP 200MG N70591 001 SEP 02, 1987
200MG N71001 001 SEP 02, 1987
@ 200MG N70591 001 SEP 02, 1987
@ 200MG N71001 001 SEP 02, 1987

INSULIN PORK

INJECTABLE; INJECTION
INSULIN
+ NOVO NORDISK 100 UNITS/ML N17926 003
REGULAR INSULIN
+ NOVO NORDISK 100 UNITS/ML N17926 003

INSULIN PURIFIED PORK

INJECTABLE; INJECTION
VELOSULIN
NOVO NORDISK 100 UNITS/ML N18193 001
@ 100 UNITS/ML N18193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION
INSULIN NORDISK MIXTARD (PORK)
+ NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N18195 001
@ 30 UNITS/ML;70 UNITS/ML N18195 001

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
MIXTARD HUMAN 70/30

+	NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19585 001	> DLT >
			MAR 11, 1988	> DLT >
@		30 UNITS/ML;70 UNITS/ML	N19585 001	> ADD >
			MAR 11, 1988	> ADD >

NOVOLIN 70/30

+	NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19441 001
			JUL 11, 1986
@		30 UNITS/ML;70 UNITS/ML	N19441 001
			JUL 11, 1986

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION
INSULIN INSULATARD NPH NORDISK

+	NOVO NORDISK	100 UNITS/ML	N18194 001
@		100 UNITS/ML	N18194 001

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION
PROTAMINE ZINC AND ILETIN II

+	LILLY	100 UNITS/ML	N18476 001
@		100 UNITS/ML	N18476 001

PROTAMINE ZINC INSULIN

	SQUIBB	100 UNITS/ML	N17928 003
+		100 UNITS/ML	N17928 003

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL

	LEMMON	1MG/5ML	N73478 001	> ADD >
			JUN 23, 1995	> ADD >

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE

	LEMMON	2%	N74136 001
			JAN 04, 1995

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

	ABLE	100MG	N73507 001
			NOV 19, 1993
	NMC	100MG	N73507 001
			NOV 19, 1993

NAPROXEN SODIUM

TABLET; ORAL
ALEVE

	HAMILTON PHARMS	EQ 200MG BASE	N20204 002
			JAN 11, 1994
+		EQ 200MG BASE	N20204 002
			JAN 11, 1994

NONOXYNOL-9

AEROSOL; VAGINAL
DELFEN

@	ORTHO	12.5%	N14349 002

POTASSIUM IODIDE

SOLUTION; ORAL
POTASSIUM IODIDE

+	ROXANE	1GM/ML	N18551 001
			FEB 19, 1982
@		1GM/ML	N18551 001
			FEB 19, 1982

PYRITHIONE ZINC

LOTION; TOPICAL
HEAD & SHOULDERS CONDITIONER

+	PROCTER AND GAMBLE	0.3%	N19412 002
			MAR 10, 1986
@		0.3%	N19412 002
			MAR 10, 1986

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
NTBC TN=	TREATMENT OF TYROSINEMIA TYPE 1.	SWEDISH ORPHAN AB ORPHAN PHARMACEUTICAL, USA, INC. NASHVILLE TN 37217 DD 05/16/95 MA / /
PHENYLALANINE AMMONIA-LYASE TN= PHENYLASE	TREATMENT OF HYPERPHENYLALANINEMIA.	IBEX TECHNOLOGIES, INC. 5485 PARE MONTREAL, QUEBEC DD 03/08/95 MA / /
PURIFIED TYPE II COLLAGEN TN= COLLORAL	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	AUTOIMMUNE, INCORPORATED 128 SPRING STREET LEXINGTON MA 02173 DD 02/09/95 MA / /
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF ACUTE AND CHRONIC RESPIRATORY SYMPTOMS OF BRONCHIECTASIS.	BIOGEN, INCORPORATED 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 03/06/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN= IGEF	TREATMENT OF ANTIBODY-MEDIATED GROWTH HORMONE RESISTANCE IN PATIENTS WITH ISOLATED GROWTH HORMONE DEFICIENCY IA.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 06/07/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN= IGEF	TREATMENT OF GROWTH HORMONE RECEPTOR DEFICIENCY.	PHARMACIA, INC. PO BOX 16529 COLUMBUS OH 43216-6529 DD 06/07/95 MA / /
RIFAPENTINE TN=	TREATMENT OF PULMONARY TUBERCULOSIS.	MARION MERRELL DOW INC. PO BOX 9627 (PARK A) KANSAS CITY MO 94137 DD 06/09/95 MA / /
RIFAPENTINE TN=	TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	MARION MERRELL DOW INC. PO BOX 9627 (PARK A) KANSAS CITY MO 64137 DD 06/09/95 MA / /
SARGRAMOSTIM TN= LEUKINE	TO REDUCE NEUTROPENIA AND LEUKOPENIA AND DECREASE THE INCIDENCE OF DEATH DUE TO INFECTION IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA.	IMMUNEX CORPORATION 51 UNIVERSITY STREET SEATTLE WA 98101 DD 03/06/95 MA / /
SU-101 TN=	TREATMENT OF MALIGNANT GLIOMA.	SUGEN, INC. 515 GALVESTON DRIVE REDWOOD CITY CA 94063-4720 DD 05/25/95 MA / /
THALIDOMIDE TN=	TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN SEVERLY, TERMINALLY IMMUNOCOMPROMISED PATIENTS.	CELGENE CORPORATION P.O. BOX 4914 WARREN NJ 07059 DD 05/01/95 MA / /
THALIDOMIDE TN=	TREATMENT AND PREVENTION OF RECURRENT APHTHOUS ULCERS IN SEVERLY, TERMINALLY IMMUNOCPOMPROMISED PATIENTS.	ANDRULIS RESEARCH CORPORATION 11800 BALTIMORE AVENUE, SUITE 113 BELTSVILLE MD 20705 DD 05/15/95 MA / /
TRISODIUM CITRATE CONCENTRATION TN= HEMOCITRATE	FOR USE IN LEUKAPHERESIS PROCEDURES.	HEMOTEC MEDICAL PRODUCTS, INC. BOX 19255 JOHNSTON RI 02919 DD 06/15/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
TYLOXAPOL TN=	TREATMENT OF CYSTIC FIBROSIS.	KENNEDY & HOIDAL, MDs 50 NORTH MEDICAL DRIVE, U OF UTAH SALT LAKE CITY UT 84132 DD 03/08/95 MA / /

Approved Orphan Products

Rho (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= WinRho SD	TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA.	RH PHARMACEUTICALS, INC. 104 CHANCELLOR MATHESON ROAD WINNIPEG, MANITOBA DD 11/09/93 MA 03/24/95

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 1995 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
CORTICOSTEROIDS, DERMATOLOGIC *IN VIVO* (TOPICAL)	JUN 02, 1995	
FLURBIPROFEN (TABLET)	DEC 24, 1992	JUN 08, 1995
NAPROXEN (TABLET)	JUN 12, 1992	JUN 08, 1995

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 1-23, PARK BUILDING, 5600 FISHERS LANE, ROCKVILLE, MD 20857.					
REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.					
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 15MG	94 P-0212/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 30MG	94 P-0211/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 60MG	94 P-0210/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE TABLET; ORAL	712.8MG 60MG 32MG	93 P-0484/ CP1	MIKART	NEW DOSAGE FORM NEW STRENGTH	APPROVED JAN 19, 1995
ACETAMINOPHEN; CODEINE PHOSPHATE TABLET, CHEWABLE; ORAL	120MG 12MG	94 P-0182/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ALBUTEROL SULFATE TABLET, CHEWABLE; ORAL	EQ 2MG BASE EQ 4MG BASE	92 P-0335/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ATRACURIUM BESLYLATE INJECTABLE; INJECTION	25MG/ML	94 P-0314/ CP1	ABBOTT	NEW STRENGTH	APPROVED MAY 02, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (100MG/VIAL)	93 P-0427/ CP3	ABBOTT	NEW DOSAGE FORM	APPROVED JAN 19, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (250MG/VIAL)	93 P-0427/ CP2	ABBOTT	NEW DOSAGE FORM NEW STRENGTH	APPROVED JAN 19, 1995
SULFAMETHOXAZOLE; TRIMETHOPRIM TABLET, CHEWABLE; ORAL	200MG 40MG	94 P-0186/ CP1	DURA PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
THIORIDAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0283/ CP1	UDL LABS	NEW STRENGTH	APPROVED JAN 19, 1995

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
NICOTINE POLACRILEX LOLLIPOP; ORAL	2MG	93 P-0414/ CP1	SAVAGE	NEW DOSAGE FORM	DENIED MAY 02, 1995

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300

REFERENCES

NEW INDICATION

I-117	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB)
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY

REFERENCES

PATENT USE CODE

U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-109	USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19872 001	ACETAMINOPHEN; TYLENOL	5004613	JUL 27, 2007			
>DLT>	~~19872 001~~	~~ACETAMINOPHEN; TYLENOL~~	~~5004613~~	~~APR 11, 2006~~			
			4968509	NOV 06, 2007			
>ADD>			4820522	JUL 27, 2007		NDF	JUN 08, 1997
>DLT>			~~4820522~~	~~APR 11, 2006~~		~~NDF~~	~~JUN 08, 1997~~
>ADD>	19806 001	ACRIVASTINE; SEMPREX-D	4501893	FEB 01, 2003			
>DLT>	~~19806 001~~	~~ACRIVASTINE; SEMPREX-D~~	~~4501893~~	~~FEB 26, 2002~~			
	20059 001	ADENOSINE; ADENOSCAN				I-126	MAY 18, 1998
>ADD>	19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS	4353365	APR 24, 1998			
>ADD>			4206758	APR 24, 1998			
>ADD>	18702 001	ALCLOMETASONE DIPROPIONATE; ACLOVATE	4124707	DEC 12, 1996			
>DLT>	~~18702 001~~	~~ALCLOMETASONE DIPROPIONATE; ACLOVATE~~	~~4124707~~	~~NOV 07, 1995~~			
>ADD>	18707 001	ALCLOMETASONE DIPROPIONATE; ACLOVATE	4124707	DEC 12, 1996			
>DLT>	~~18707 001~~	~~ALCLOMETASONE DIPROPIONATE; ACLOVATE~~	~~4124707~~	~~NOV 07, 1995~~			
>ADD>	19787 001	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
>DLT>	~~19787 001~~	~~AMLODIPINE BESYLATE; NORVASC~~	~~4879303~~	~~NOV 07, 2006~~			
>ADD>	19787 002	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
>DLT>	~~19787 002~~	~~AMLODIPINE BESYLATE; NORVASC~~	~~4879303~~	~~NOV 07, 2006~~			
>ADD>	19787 003	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
>DLT>	~~19787 003~~	~~AMLODIPINE BESYLATE; NORVASC~~	~~4879303~~	~~NOV 07, 2006~~			
>ADD>	20364 002	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007		NC	MAR 03, 1998
>DLT>	~~20364 002~~	~~AMLODIPINE BESYLATE; LOTREL~~	~~4879303~~	~~NOV 07, 2006~~		~~NC~~	~~MAR 03, 1998~~
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	OCT 18, 2002		NCE	JUL 31, 1997
>ADD>	20364 003	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007		NC	MAR 03, 1998
>DLT>	~~20364 003~~	~~AMLODIPINE BESYLATE; LOTREL~~	~~4879303~~	~~NOV 07, 2006~~		~~NC~~	~~MAR 03, 1998~~
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	OCT 18, 2002		NCE	JUL 31, 1997
>ADD>	20364 004	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007		NC	MAR 03, 1998
>DLT>	~~20364 004~~	~~AMLODIPINE BESYLATE; LOTREL~~	~~4879303~~	~~NOV 07, 2006~~		~~NC~~	~~MAR 03, 1998~~
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	OCT 18, 2002		NCE	JUL 31, 1997
>ADD>	20259 001	ATOVAQUONE; MEPRON	4981874	AUG 15, 2009	U-69		
>DLT>	~~20259 001~~	~~ATOVAQUONE; MEPRON~~	~~4981874~~	~~JAN 01, 2008~~	~~U-69~~		
	20500 001	ATOVAQUONE; MEPRON	5053432	OCT 01, 2008		NCE	NOV 25, 1997
			4981874	AUG 15, 2009	U-69	NDF	FEB 08, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	18644 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
>DLT>	~~18644 001~~	~~BUPROPION HYDROCHLORIDE; WELLBUTRIN~~	~~4507323~~	~~MAR 26, 2002~~			
>ADD>			4438138	DEC 06, 2002			
>DLT>			~~4438138~~	~~MAR 20, 2001~~			
>ADD>			4435449	MAY 14, 2001			
>DLT>			~~4435449~~	~~MAR 06, 2001~~			
>ADD>			4425363	MAY 14, 2001			
>DLT>			~~4425363~~	~~JAN 10, 2001~~			
>ADD>			4393078	MAR 15, 2002			
>DLT>			~~4393078~~	~~JUL 12, 2000~~			
>ADD>			4347257	OCT 09, 1999			
>DLT>			~~4347257~~	~~AUG 31, 1999~~			
>ADD>	18644 002	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
>DLT>	~~18644 002~~	~~BUPROPION HYDROCHLORIDE; WELLBUTRIN~~	~~4507323~~	~~MAR 26, 2002~~			
>ADD>			4438138	DEC 06, 2002			
>DLT>			~~4438138~~	~~MAR 20, 2001~~			
>ADD>			4435449	MAY 14, 2001			
>DLT>			~~4435449~~	~~MAR 06, 2001~~			
>ADD>			4425363	MAY 14, 2001			
>DLT>			~~4425363~~	~~JAN 10, 2001~~			
>ADD>			4393078	MAR 15, 2002			
>DLT>			~~4393078~~	~~JUL 12, 2000~~			
>ADD>			4347257	OCT 09, 1999			
>DLT>			~~4347257~~	~~AUG 31, 1999~~			
>ADD>	18644 003	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
>DLT>	~~18644 003~~	~~BUPROPION HYDROCHLORIDE; WELLBUTRIN~~	~~4507323~~	~~MAR 26, 2002~~			
>ADD>			4438138	DEC 06, 2002			
>DLT>			~~4438138~~	~~MAR 20, 2001~~			
>ADD>			4435449	MAY 14, 2001			
>DLT>			~~4435449~~	~~MAR 06, 2001~~			
>ADD>			4425363	MAY 14, 2001			
>DLT>			~~4425363~~	~~JAN 10, 2001~~			
>ADD>			4393078	MAR 15, 2002			
>DLT>			~~4393078~~	~~JUL 12, 2000~~			
>ADD>			4347257	OCT 09, 1999			
>DLT>			~~4347257~~	~~AUG 31, 1999~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	18343 001	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
>DLT>	~~18343 001~~	~~CAPTOPRIL; CAPOTEN~~	~~4105776~~	~~AUG 08, 1995~~			
>ADD>	18343 002	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
>DLT>	~~18343 002~~	~~CAPTOPRIL; CAPOTEN~~	~~4105776~~	~~AUG 08, 1995~~			
>ADD>	18343 003	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
>DLT>	~~18343 003~~	~~CAPTOPRIL; CAPOTEN~~	~~4105776~~	~~AUG 08, 1995~~			
>ADD>	18343 005	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
>DLT>	~~18343 005~~	~~CAPTOPRIL; CAPOTEN~~	~~4105776~~	~~AUG 08, 1995~~			
>ADD>	18343 006	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
>DLT>	~~18343 006~~	~~CAPTOPRIL; CAPOTEN~~	~~4105776~~	~~AUG 08, 1995~~			
>ADD>	18709 001	CAPTOPRIL; CAPOZIDE 25/15	4217347	DEC 27, 1997			
>DLT>	~~18709 001~~	~~CAPTOPRIL; CAPOZIDE 25/15~~	~~4217347~~	~~AUG 12, 1997~~			
>ADD>			4105776	FEB 13, 1996			
>DLT>			~~4105776~~	~~AUG 08, 1995~~			
>ADD>	18709 002	CAPTOPRIL; CAPOZIDE 25/25	4217347	DEC 27, 1997			
>DLT>	~~18709 002~~	~~CAPTOPRIL; CAPOZIDE 25/25~~	~~4217347~~	~~AUG 12, 1997~~			
>ADD>			4105776	FEB 13, 1996			
>DLT>			~~4105776~~	~~AUG 08, 1995~~			
>ADD>	18709 003	CAPTOPRIL; CAPOZIDE 50/25	4217347	DEC 27, 1997			
>DLT>	~~18709 003~~	~~CAPTOPRIL; CAPOZIDE 50/25~~	~~4217347~~	~~AUG 12, 1997~~			
>ADD>			4105776	FEB 13, 1996			
>DLT>			~~4105776~~	~~AUG 08, 1995~~			
>ADD>	18709 004	CAPTOPRIL; CAPOZIDE 50/15	4217347	DEC 27, 1997			
>DLT>	~~18709 004~~	~~CAPTOPRIL; CAPOZIDE 50/15~~	~~4217347~~	~~AUG 12, 1997~~			
>ADD>			4105776	FEB 13, 1996			
>DLT>			~~4105776~~	~~AUG 08, 1995~~			
>ADD>	19856 001	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
>DLT>	~~19856 001~~	~~CARBIDOPA; SINEMET CR~~	~~4900755~~	~~MAY 23, 2006~~			
>ADD>			4832957	JUN 16, 2006			
>DLT>			~~4832957~~	~~MAY 23, 2006~~			
>ADD>	19856 002	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
>DLT>	~~19856 002~~	~~CARBIDOPA; SINEMET CR~~	~~4900755~~	~~MAY 23, 2006~~			
>ADD>			4832957	JUN 16, 2006			
>DLT>			~~4832957~~	~~MAY 23, 2006~~			
>ADD>	20044 001	CETYL ALCOHOL; EXOSURF NEONATAL	5110806	MAY 02, 2006			
>ADD>	18663 001	CHYMOPAPAIN; CHYMODIACTIN	4439423	MAY 13, 2001			
>DLT>	~~18663 001~~	~~CHYMOPAPAIN; CHYMODIACTIN~~	~~4439423~~	~~MAR 26, 2001~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	18663 002	CHYMOPAPAIN; CHYMODIACTIN	4439423	MAY 13, 2001			
>DLT>	~~18663 002~~	~~CHYMOPAPAIN; CHYMODIACTIN~~	~~4439423~~	~~MAR 26, 2001~~			
>ADD>	20238 001	CIMETIDINE; TAGAMET HB				NS	JUN 19, 1998
>ADD>	18891 001	CLONIDINE; CATAPRES-TTS-1	4559222	MAY 04, 2003			
>DLT>	~~18891 001~~	~~CLONIDINE; CATAPRES-TTS-1~~	~~4559222~~	~~DEC 17, 2002~~			
>ADD>			4201211	JUL 12, 1997			
>DLT>			~~4201211~~	~~MAY 06, 1997~~			
>ADD>	18891 002	CLONIDINE; CATAPRES-TTS-2	4559222	MAY 04, 2003			
>DLT>	~~18891 002~~	~~CLONIDINE; CATAPRES-TTS-2~~	~~4559222~~	~~DEC 17, 2002~~			
>ADD>			4201211	JUL 12, 1997			
>DLT>			~~4201211~~	~~MAY 06, 1997~~			
>ADD>	18891 003	CLONIDINE; CATAPRES-TTS-3	4559222	MAY 04, 2003			
>DLT>	~~18891 003~~	~~CLONIDINE; CATAPRES-TTS-3~~	~~4559222~~	~~DEC 17, 2002~~			
>ADD>			4201211	JUL 12, 1997			
>DLT>			~~4201211~~	~~MAY 06, 1997~~			
	20222 001	COLESTIPOL HYDROCHLORIDE; COLESTID				NDF	JUL 19, 1997
>ADD>	12142 006	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
>DLT>	~~12142 006~~	~~CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN~~	~~4537883~~	~~AUG 27, 2002~~			
>ADD>	12142 007	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
>DLT>	~~12142 007~~	~~CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN~~	~~4537883~~	~~AUG 27, 2002~~			
>ADD>	12142 008	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
>DLT>	~~12142 008~~	~~CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN~~	~~4537883~~	~~AUG 27, 2002~~			
>ADD>	12142 009	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
>DLT>	~~12142 009~~	~~CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN~~	~~4537883~~	~~AUG 27, 2002~~			
>ADD>	12142 010	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
>DLT>	~~12142 010~~	~~CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN~~	~~4537883~~	~~AUG 27, 2002~~			
	20287 001	DALTEPARIN SODIUM; FRAGMIN	4303651	JAN 04, 2000		NCE	DEC 22, 1999
>ADD>	19849 001	DAPIPRAZOLE HYDROCHLORIDE; REV-EYES	4252721	FEB 07, 2003			
>DLT>	~~19849 001~~	~~DAPIPRAZOLE HYDROCHLORIDE; REV-EYES~~	~~4252721~~	~~JAN 06, 2002~~			
	20212 001	DEXRAZOXANE HYDROCHLORIDE; ZINECARD				NCE	MAY 26, 2000
	20212 002	DEXRAZOXANE HYDROCHLORIDE; ZINECARD				NCE	MAY 26, 2000
>ADD>	20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	MAY 20, 2011			
>DLT>	~~20062 001~~	~~DILTIAZEM HYDROCHLORIDE; CARDIZEM CD~~	~~5286497~~	~~FEB 14, 2011~~			
>ADD>	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	MAY 20, 2011			
>DLT>	~~20062 002~~	~~DILTIAZEM HYDROCHLORIDE; CARDIZEM CD~~	~~5286497~~	~~FEB 14, 2011~~			
>ADD>	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	MAY 20, 2011			
>DLT>	~~20062 003~~	~~DILTIAZEM HYDROCHLORIDE; CARDIZEM CD~~	~~5286497~~	~~FEB 14, 2011~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	MAY 20, 2011			
>DLT>	~~20062 004~~	~~DILTIAZEM HYDROCHLORIDE; CARDIZEM CD~~	~~5286497~~	~~FEB 14, 2011~~			
>ADD>	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-120	OCT 15, 1995
>DLT>	~~20092 001~~	~~DILTIAZEM HYDROCHLORIDE; DILACOR XR~~	~~4839177~~	~~JUN 13, 2006~~		~~I-120~~	~~OCT 15, 1995~~
>ADD>	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-120	OCT 15, 1995
>DLT>	~~20092 002~~	~~DILTIAZEM HYDROCHLORIDE; DILACOR XR~~	~~4839177~~	~~JUN 13, 2006~~		~~I-120~~	~~OCT 15, 1995~~
>ADD>	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-120	OCT 15, 1995
>DLT>	~~20092 003~~	~~DILTIAZEM HYDROCHLORIDE; DILACOR XR~~	~~4839177~~	~~JUN 13, 2006~~		~~I-120~~	~~OCT 15, 1995~~
>ADD>	20411 001	DINOPROSTONE; CERVIDIL	5269321	DEC 14, 2010	U-110		
>ADD>			4931288	JAN 16, 2007		NDF	MAR 30, 1998
	20408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4797413	JUN 30, 2004	U-103	NCE	DEC 09, 1999
			4619939	OCT 28, 2003	U-104		
	19946 001	DOXACURIUM CHLORIDE; NUROMAX				I-121	DEC 08, 1997
	19668 001	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998
	19668 002	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998
	19668 003	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998
	19668 004	DOXAZOSIN MESYLATE; CARDURA				I-96	FEB 06, 1998
>ADD>	19616 004	ENOXACIN; PENETREX	4442101	FEB 04, 2002			
>DLT>	~~19616 004~~	~~ENOXACIN; PENETREX~~	~~4442101~~	~~APR 10, 2001~~			
>ADD>	19616 005	ENOXACIN; PENETREX	4442101	FEB 04, 2002			
>DLT>	~~19616 005~~	~~ENOXACIN; PENETREX~~	~~4442101~~	~~APR 10, 2001~~			
	20164 001	ENOXAPARIN SODIUM; LOVENOX				I-118	MAR 09, 1998
>ADD>	18418 001	ERGOLOID MESYLATES; HYDERGINE	4138565	MAY 26, 1996			
>DLT>	~~18418 001~~	~~ERGOLOID MESYLATES; HYDERGINE~~	~~4138565~~	~~FEB 06, 1996~~			
>ADD>	18706 001	ERGOLOID MESYLATES; HYDERGINE LC	4366145	JUN 24, 2001			
>DLT>	~~18706 001~~	~~ERGOLOID MESYLATES; HYDERGINE LC~~	~~4366145~~	~~DEC 28, 1999~~			
>ADD>	19081 002	ESTRADIOL; ESTRADERM	4379454	FEB 17, 2001			
>DLT>	~~19081 002~~	~~ESTRADIOL; ESTRADERM~~	~~4379454~~	~~APR 12, 2000~~			
>ADD>	19081 003	ESTRADIOL; ESTRADERM	4379454	FEB 17, 2001			
>DLT>	~~19081 003~~	~~ESTRADIOL; ESTRADERM~~	~~4379454~~	~~APR 12, 2000~~			
	20323 001	ESTRADIOL; VIVELLE	5300291	APR 05, 2011		NS	OCT 28, 1997
>ADD>			4994278	MAR 04, 2008			
>DLT>			~~4994278~~	~~FEB 19, 2008~~			
>ADD>			4994267	MAR 04, 2008			
>DLT>			~~4994267~~	~~FEB 19, 2008~~			
>ADD>			4814168	MAR 04, 2008			
>DLT>			~~4814168~~	~~MAR 21, 2006~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20323 002	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
>ADD>			4994278	MAR 04, 2008			
>DLT>			~~4994278~~	~~FEB 19, 2008~~			
>ADD>			4994267	MAR 04, 2008			
>DLT>			~~4994267~~	~~FEB 19, 2008~~			
>ADD>			4814168	MAR 04, 2008			
>DLT>			~~4814168~~	~~MAR 21, 2006~~			
	20323 003	ESTRADIOL; VIVELLE	5300291	APR 05, 2011		NS	OCT 28, 1997
>ADD>			4994278	MAR 04, 2008			
>DLT>			~~4994278~~	~~FEB 19, 2008~~			
>ADD>			4994267	MAR 04, 2008			
>DLT>			~~4994267~~	~~FEB 19, 2008~~			
>ADD>			4814168	MAR 04, 2008			
>DLT>			~~4814168~~	~~MAR 21, 2006~~			
	20323 004	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
>ADD>			4994278	MAR 04, 2008			
>DLT>			~~4994278~~	~~FEB 19, 2008~~			
>ADD>			4994267	MAR 04, 2008			
>DLT>			~~4994267~~	~~FEB 19, 2008~~			
>ADD>			4814168	MAR 04, 2008			
>DLT>			~~4814168~~	~~MAR 21, 2006~~			
	20375 001	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997
	20375 002	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997
>ADD>	86069 001	ESTRADIOL; ESTRACE	4436738	MAR 15, 2002			
>DLT>	~~86069 001~~	~~ESTRADIOL; ESTRACE~~	~~4436738~~	~~MAR 13, 2001~~			
	20303 001	ESTROGENS, CONJUGATED; PREMPRO (PREMARIN;CYCRIN 14/14)	4826831	MAY 02, 2006	U-102	NP	DEC 30, 1997
>ADD>	18977 001	ETHINYL ESTRADIOL; TRI-NORINYL 21-DAY	4390531	AUG 10, 2001			
>DLT>	~~18977 001~~	~~ETHINYL ESTRADIOL; TRI-NORINYL 21-DAY~~	~~4390531~~	~~JUN 28, 2000~~			
>ADD>	18977 002	ETHINYL ESTRADIOL; TRI-NORINYL 28-DAY	4390531	AUG 10, 2001			
>DLT>	~~18977 002~~	~~ETHINYL ESTRADIOL; TRI-NORINYL 28-DAY~~	~~4390531~~	~~JUN 28, 2000~~			
	20325 001	FAMOTIDINE; PEPCID AC	4283408	AUG 11, 2000		NS	APR 28, 1998
>ADD>	20189 001	FELBAMATE; FELBATOL	5082861	DEC 07, 2010	U-83		
>DLT>	~~20189 001~~	~~FELBAMATE; FELBATOL~~	~~5082861~~	~~JAN 21, 2009~~	~~U-83~~		
>ADD>			4978680	SEP 26, 2009	U-83		
>DLT>			~~4978680~~	~~DEC 18, 2007~~	~~U-83~~		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20189 002	FELBAMATE; FELBATOL	5082861	DEC 07, 2010	U-83		
>DLT>	20189 002	FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83		
>ADD>			4978680	SEP 26, 2009	U-83		
>DLT>			4978680	DEC 18, 2007	U-83		
>ADD>	20189 003	FELBAMATE; FELBATOL	5082861	DEC 07, 2010	U-83		
>DLT>	20189 003	FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83		
>ADD>			4978680	SEP 26, 2009	U-83		
>DLT>			4978680	DEC 18, 2007	U-83		
>ADD>	19834 001	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
>DLT>	19834 001	FELODIPINE; PLENDIL	4803081	FEB 07, 2006			
			4264611	APR 28, 1998	U-3	NCE	JUL 25, 1996
>ADD>	19834 002	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
>DLT>	19834 002	FELODIPINE; PLENDIL	4803081	FEB 07, 2006			
			4264611	APR 28, 1998	U-3	NCE	JUL 25, 1996
>ADD>	19834 004	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
>DLT>	19834 004	FELODIPINE; PLENDIL	4803081	FEB 07, 2006			
			4264611	APR 28, 1998	U-3	NCE	JUL 25, 1996
>ADD>	19813 001	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
>DLT>	19813 001	FENTANYL; DURAGESIC	4588580	MAY 13, 2003	U-43		
>ADD>	19813 002	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
>DLT>	19813 002	FENTANYL; DURAGESIC	4588580	MAY 13, 2003	U-43		
>ADD>	19813 003	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
>DLT>	19813 003	FENTANYL; DURAGESIC	4588580	MAY 13, 2003	U-43		
>ADD>	19813 004	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
>DLT>	19813 004	FENTANYL; DURAGESIC	4588580	MAY 13, 2003	U-43		
>ADD>	19960 001	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
>DLT>	19960 001	FLOSEQUINAN; MANOPLAX	4302460	NOV 24, 1998			
>ADD>	19960 002	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
>DLT>	19960 002	FLOSEQUINAN; MANOPLAX	4302460	NOV 24, 1998			
>ADD>	19960 003	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
>DLT>	19960 003	FLOSEQUINAN; MANOPLAX	4302460	NOV 24, 1998			
>ADD>	19960 004	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
>DLT>	19960 004	FLOSEQUINAN; MANOPLAX	4302460	NOV 24, 1998			
>ADD>	18148 001	FLUNISOLIDE; NASALIDE	4933168	JUN 12, 2007			
>ADD>	18340 001	FLUNISOLIDE; AEROBID	4933168	JUN 12, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20409 001	FLUNISOLIDE; NASAREL	4983595	MAY 22, 2006			
>ADD>			4933168	JUN 12, 2007			
>ADD>			4782047	MAY 22, 2006			
	19452 001	FLUOCINOLONE ACETONIDE; DERMA-SMOOTHE/FS				I-122	FEB 16, 1998
	20121 001	FLUTICASONE PROPIONATE; FLONASE	4335121	MAR 15, 2002		NCE	DEC 14, 1995
						NDF	OCT 19, 1997
	20261 001	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
	20261 002	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
>ADD>	20068 001	FOSCARNET SODIUM; FOSCAVIR	4339445	JUL 29, 1997	U-64	I-127	JUN 16, 1998
>ADD>	19915 002	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
>DLT>	~~19915 002~~	~~FOSINOPRIL SODIUM; MONOPRIL~~	~~5006344~~	~~APR 09, 2008~~			
>ADD>			4384123	DEC 04, 2000		I-92	MAY 02, 1998
>DLT>			~~4384123~~	~~MAY 17, 2000~~		~~I-92~~	~~MAY 02, 1998~~
>ADD>	19915 003	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
>DLT>	~~19915 003~~	~~FOSINOPRIL SODIUM; MONOPRIL~~	~~5006344~~	~~APR 09, 2008~~			
>ADD>			4384123	DEC 04, 2000		I-92	MAY 02, 1998
>DLT>			~~4384123~~	~~MAY 17, 2000~~		~~I-92~~	~~MAY 02, 1998~~
>ADD>	19915 004	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
>DLT>	~~19915 004~~	~~FOSINOPRIL SODIUM; MONOPRIL~~	~~5006344~~	~~APR 09, 2008~~			
>ADD>			4384123	DEC 04, 2000		I-92	MAY 02, 1998
>DLT>			~~4384123~~	~~MAY 17, 2000~~		~~I-92~~	~~MAY 02, 1998~~
			4337201	JUN 29, 2001		NCE	MAY 16, 1996
>ADD>	20286 001	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	JUL 10, 2009			
>DLT>	~~20286 001~~	~~FOSINOPRIL SODIUM; MONOPRIL-HCT~~	~~5006344~~	~~APR 09, 2008~~			
>ADD>			4384123	DEC 04, 2000			
>DLT>			~~4384123~~	~~MAY 17, 2000~~			
>ADD>	20286 002	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	JUL 10, 2009			
>DLT>	~~20286 002~~	~~FOSINOPRIL SODIUM; MONOPRIL-HCT~~	~~5006344~~	~~APR 09, 2008~~			
>ADD>			4384123	DEC 04, 2000			
>DLT>			~~4384123~~	~~MAY 17, 2000~~			
>ADD>	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	5362475	NOV 08, 2011			
	20460 001	GANCICLOVIR; CYTOVENE	4507305	OCT 19, 1999	U-64	NDF	DEC 22, 1997
			4355032	MAR 16, 2003	U-64		
>ADD>	19661 001	GANCICLOVIR SODIUM; CYTOVENE	4507305	MAY 21, 2001	U-35		
>DLT>	~~19661 001~~	~~GANCICLOVIR SODIUM; CYTOVENE~~	~~4507305~~	~~OCT 19, 1999~~	~~U-35~~		
>ADD>			4423050	MAY 21, 2001	U-34		
>DLT>			~~4423050~~	~~OCT 19, 1999~~	~~U-34~~		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 12, 2006	U-105	NCE	DEC 29, 1998
						NDF	MAR 16, 1998
>ADD>	19059 001	HYDROCHLOROTHIAZIDE; INDERIDE LA 80/50	4138475	SEP 14, 1997			
>DLT>	~~19059 001~~	~~HYDROCHLOROTHIAZIDE; INDERIDE LA 80/50~~	~~4138475~~	~~FEB 06, 1996~~			
>ADD>	19059 002	HYDROCHLOROTHIAZIDE; INDERIDE LA 120/50	4138475	SEP 14, 1997			
>DLT>	~~19059 002~~	~~HYDROCHLOROTHIAZIDE; INDERIDE LA 120/50~~	~~4138475~~	~~FEB 06, 1996~~			
>ADD>	19059 003	HYDROCHLOROTHIAZIDE; INDERIDE LA 160/50	4138475	SEP 14, 1997			
>DLT>	~~19059 003~~	~~HYDROCHLOROTHIAZIDE; INDERIDE LA 160/50~~	~~4138475~~	~~FEB 06, 1996~~			
>ADD>	19129 001	HYDROCHLOROTHIAZIDE; MAXZIDE	4444769	JUL 27, 2002			
>DLT>	~~19129 001~~	~~HYDROCHLOROTHIAZIDE; MAXZIDE~~	~~4444769~~	~~APR 24, 2001~~			
>ADD>	19129 003	HYDROCHLOROTHIAZIDE; MAXZIDE-25	4444769	JUL 27, 2002			
>DLT>	~~19129 003~~	~~HYDROCHLOROTHIAZIDE; MAXZIDE-25~~	~~4444769~~	~~APR 24, 2001~~			
	20387 001	HYDROCHLOROTHIAZIDE; HYZAAR	5153197	OCT 06, 2009	U-3	NC	APR 28, 1998
			5138069	AUG 11, 2009		NCE	APR 14, 2000
	19842 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		I-123	MAR 24, 1998
	20135 001	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
			5215755	JUN 01, 2010		NDF	NOV 16, 1997
	20135 002	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
			5215755	JUN 01, 2010		NDF	NOV 16, 1997
	20418 001	IBUPROFEN; MOTRIN				I-123	MAR 24, 1998
>ADD>	20516 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
>ADD>	18185 001	INDOMETHACIN; INDOCIN SR	4173626	DEC 11, 1998			
>DLT>	~~18185 001~~	~~INDOMETHACIN; INDOCIN SR~~	~~4173626~~	~~NOV 06, 1996~~			
	18956 007	IOHEXOL; OMNIPAQUE 70	4396597	JUL 14, 1998			
			4250113	DEC 26, 1999			
>ADD>	18735 004	IOPAMIDOL; ISOVUE-M 300	4001323	JAN 04, 1996		D-28	MAY 15, 1998
	20220 001	IOPROMIDE; ULTRAVIST				NCE	MAY 10, 2000
	20220 002	IOPROMIDE; ULTRAVIST				NCE	MAY 10, 2000
	20220 003	IOPROMIDE; ULTRAVIST				NCE	MAY 10, 2000
	20220 004	IOPROMIDE; ULTRAVIST				NCE	MAY 10, 2000
>ADD>	19710 005	IOVERSOL; OPTIRAY 350				I-131	JUN 21, 1998
	20225 003	ISOSORBIDE MONONITRATE; IMDUR				NDF	AUG 12, 1996
						NCE	DEC 30, 1996
>ADD>	20336 001	ISRADIPINE; DYNACIRC CR	4816263	OCT 02, 2007	U-3		
>DLT>	~~20336 001~~	~~ISRADIPINE; DYNACIRC CR~~	~~4816263~~	~~MAR 28, 2006~~	~~U-3~~		
>ADD>	20336 002	ISRADIPINE; DYNACIRC CR	4816263	OCT 02, 2007	U-3		
>DLT>	~~20336 002~~	~~ISRADIPINE; DYNACIRC CR~~	~~4816263~~	~~MAR 28, 2006~~	~~U-3~~		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19816 002	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	19816 003	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
>ADD>	19698 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NR	DEC 07, 1997
>ADD>	19698 002	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NR	DEC 07, 1997
>ADD>	19700 001	KETOROLAC TROMETHAMINE; ACULAR	4454151	MAR 22, 2002	U-75		
>DLT>			~~4454151~~	~~JUN 12, 2001~~	~~U-75~~		
>ADD>	18686 001	LABETALOL HYDROCHLORIDE; NORMODYNE	4328213	NOV 28, 1999			
>DLT>	~~18686 001~~	~~LABETALOL HYDROCHLORIDE; NORMODYNE~~	~~4328213~~	~~MAY 04, 1999~~			
	20241 001	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 002	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 003	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 004	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 005	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 006	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
>ADD>	20406 001	LANSOPRAZOLE; PREVACID	5093132	SEP 03, 2008			
>ADD>			5045321	SEP 03, 2008			
>ADD>			5026560	JUN 25, 2008			
>ADD>			4689333	JUL 29, 2005			
>ADD>			4628098	JUL 29, 2005		NCE	MAY 10, 2000
>ADD>	20406 002	LANSOPRAZOLE; PREVACID	5093132	SEP 03, 2008			
>ADD>			5045321	SEP 03, 2008			
>ADD>			5026560	JUN 25, 2008			
>ADD>			4689333	JUL 29, 2005			
>ADD>			4628098	JUL 29, 2005		NCE	MAY 10, 2000
>ADD>	19732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5330767	NOV 01, 2004			
>ADD>			4917893	NOV 01, 2004			
>DLT>			~~4917893~~	~~MAR 24, 2004~~			
>ADD>			4728721	MAY 01, 2006			
>DLT>			~~4728721~~	~~MAR 01, 2005~~			
>ADD>			4677191	JUL 03, 2005			
>DLT>			~~4677191~~	~~JUN 30, 2004~~			
>ADD>			4652441	NOV 01, 2004			
>DLT>			~~4652441~~	~~MAR 24, 2004~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5330767	NOV 01, 2004			
>ADD>			4917893	NOV 01, 2004			
>DLT>			~~4917893~~	~~MAR 24, 2004~~			
>ADD>			4728721	MAY 01, 2006			
>DLT>			~~4728721~~	~~MAR 01, 2005~~			
>ADD>			4677191	JUL 03, 2005			
>DLT>			~~4677191~~	~~JUN 30, 2004~~			
>ADD>			4652441	NOV 01, 2004			
>DLT>			~~4652441~~	~~MAR 24, 2004~~			
			4005063	JAN 25, 1996		I-119	MAR 30, 1998
>ADD>	20263 001	LEUPROLIDE ACETATE; LUPRON	5330767	NOV 01, 2004			
>ADD>			4917893	NOV 01, 2004			
>DLT>			~~4917893~~	~~MAR 24, 2004~~			
>ADD>			4728721	MAY 01, 2006			
>DLT>			~~4728721~~	~~MAR 01, 2005~~			
>ADD>			4677191	JUL 03, 2005			
>DLT>			~~4677191~~	~~JUN 30, 2004~~			
>ADD>			4652441	NOV 01, 2004			
>DLT>			~~4652441~~	~~MAR 24, 2004~~			
>ADD>	20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
>ADD>			4917893	NOV 01, 2004			
>DLT>			~~4917893~~	~~MAR 24, 2004~~			
>ADD>			4728721	MAY 01, 2006			
>DLT>			~~4728721~~	~~MAR 01, 2005~~			
>ADD>			4677191	JUL 03, 2005			
>DLT>			~~4677191~~	~~JUN 30, 2004~~			
>ADD>			4652441	NOV 01, 2004			
>DLT>			~~4652441~~	~~MAR 24, 2004~~			
>ADD>	20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
>ADD>			4917893	NOV 01, 2004			
>DLT>			~~4917893~~	~~MAR 24, 2004~~			
>ADD>			4728721	MAY 01, 2006			
>DLT>			~~4728721~~	~~MAR 01, 2005~~			
>ADD>			4677191	JUL 03, 2005			
>DLT>			~~4677191~~	~~JUN 30, 2004~~			
>ADD>			4652441	NOV 01, 2004			
>DLT>			~~4652441~~	~~MAR 24, 2004~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
>ADD>			4917893	NOV 01, 2004			
>DLT>			~~4917893~~	~~MAR 24, 2004~~			
>ADD>			4728721	MAY 01, 2006			
>DLT>			~~4728721~~	~~MAR 01, 2005~~			
>ADD>			4677191	JUL 03, 2005			
>DLT>			~~4677191~~	~~JUN 30, 2004~~			
>ADD>			4652441	NOV 01, 2004			
>DLT>			~~4652441~~	~~MAR 24, 2004~~			
>ADD>	20263 005	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
>ADD>			4917893	NOV 01, 2004			
>DLT>			~~4917893~~	~~MAR 24, 2004~~			
>ADD>			4728721	MAY 01, 2006			
>DLT>			~~4728721~~	~~MAR 01, 2005~~			
>ADD>			4677191	JUL 03, 2005			
>DLT>			~~4677191~~	~~JUN 30, 2004~~			
>ADD>			4652441	NOV 01, 2004			
>DLT>			~~4652441~~	~~MAR 24, 2004~~			
>ADD>	20263 006	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5330767	NOV 01, 2004			
>ADD>			4917893	NOV 01, 2004			
>DLT>			~~4917893~~	~~MAR 24, 2004~~			
>ADD>			4728721	MAY 01, 2006			
>DLT>			~~4728721~~	~~MAR 01, 2005~~			
>ADD>			4677191	JUL 03, 2005			
>DLT>			~~4677191~~	~~JUN 30, 2004~~			
>ADD>			4652441	NOV 01, 2004			
>DLT>			~~4652441~~	~~MAR 24, 2004~~			
>ADD>	18027 001	LITHIUM CARBONATE; LITHOBID	4264573	MAY 21, 1999			
>DLT>	~~18027 001~~	~~LITHIUM CARBONATE; LITHOBID~~	~~4264573~~	~~APR 28, 1998~~			
	19670 001	LORATADINE; CLARITIN-D	4282233	AUG 04, 2000		NCE	APR 12, 1998
	20386 001	LOSARTAN POTASSIUM; COZAAR	5153197	OCT 06, 2009	U-3		
			5138069	AUG 11, 2009		NCE	APR 14, 2000
	20386 002	LOSARTAN POTASSIUM; COZAAR	5153197	OCT 06, 2009	U-3		
			5138069	AUG 11, 2009		NCE	APR 14, 2000
	19643 002	LOVASTATIN; MEVACOR	4231938	NOV 04, 1999		I-117	FEB 08, 1998
	19643 003	LOVASTATIN; MEVACOR	4231938	NOV 04, 1999		I-117	FEB 08, 1998
	19643 004	LOVASTATIN; MEVACOR	4231938	NOV 04, 1999		I-117	FEB 08, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19940 001	MASOPROCOL; ACTINEX	4695590	SEP 04, 2006		NCE	SEP 04, 1997
>DLT>	19940 001	MASOPROCOL; ACTINEX	4695590	SEP 05, 2006		NCE	SEP 04, 1997
>ADD>	19591 001	MEFLOQUINE HYDROCHLORIDE; LARIAM	4579855	OCT 01, 2004			
>ADD>	20207 001	MELPHALAN HYDROCHLORIDE; ALKERAN	4997651	NOV 18, 2008			
>DLT>	20207 001	MELPHALAN HYDROCHLORIDE; ALKERAN	4997651	MAR 05, 2008			
>ADD>	18029 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN-SR	4137300	AUG 20, 1996			
>DLT>	18029 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN-SR	4137300	JAN 30, 1996			
	19962 001	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
			5001161	MAR 19, 2008			
			4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
	19962 002	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
			5001161	MAR 19, 2008			
			4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
	19962 003	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
			5001161	MAR 19, 2008			
			4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
	18654 001	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
	18654 002	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
>ADD>	19268 001	MISOPROSTOL; CYTOTEC	4301146	JUL 29, 2000			
>DLT>	19268 001	MISOPROSTOL; CYTOTEC	4301146	NOV 17, 1998			
>ADD>	19268 003	MISOPROSTOL; CYTOTEC	4301146	JUL 29, 2000			
>ADD>	20312 001	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4743450	MAY 24, 2007		NCE	APR 19, 2000
>ADD>	20312 002	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4743450	MAY 24, 2007		NCE	APR 19, 2000
	20459 001	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
	20459 002	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
>ADD>	18932 001	NALTREXONE HYDROCHLORIDE; REVIA				I-129	DEC 30, 1997
>ADD>	20152 001	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001	U-12	NCE	DEC 22, 1999
>DLT>	20152 001	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	JUL 06, 1999	U-12	NCE	DEC 22, 1999
>ADD>	20152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001	U-12	NCE	DEC 22, 1999
>DLT>	20152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	JUL 06, 1999	U-12	NCE	DEC 22, 1999
>ADD>	20152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001	U-12	NCE	DEC 22, 1999
>DLT>	20152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	JUL 06, 1999	U-12	NCE	DEC 22, 1999
>ADD>	20152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001	U-12	NCE	DEC 22, 1999
>DLT>	20152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	JUL 06, 1999	U-12	NCE	DEC 22, 1999
>ADD>	20152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001	U-12	NCE	DEC 22, 1999
>DLT>	20152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	JUL 06, 1999	U-12	NCE	DEC 22, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001	U-12	NCE	DEC 22, 1999
>DLT>	~~20152 006~~	~~NEFAZODONE HYDROCHLORIDE; SERZONE~~	~~4338317~~	~~JUL 06, 1999~~	~~U-12~~	~~NCE~~	~~DEC 22, 1999~~
>ADD>	20076 001	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
>DLT>	~~20076 001~~	~~NICOTINE; HABITROL~~	~~4597961~~	~~JUL 01, 2003~~	~~U-56~~		
>ADD>	20076 002	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
>DLT>	~~20076 002~~	~~NICOTINE; HABITROL~~	~~4597961~~	~~JUL 01, 2003~~	~~U-56~~		
>ADD>	20076 003	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
>DLT>	~~20076 003~~	~~NICOTINE; HABITROL~~	~~4597961~~	~~JUL 01, 2003~~	~~U-56~~		
>ADD>	20150 001	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
>DLT>	~~20150 001~~	~~NICOTINE; NICOTROL~~	~~4915950~~	~~APR 10, 2007~~			
>ADD>	20150 002	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
>DLT>	~~20150 002~~	~~NICOTINE; NICOTROL~~	~~4915950~~	~~APR 10, 2007~~			
>ADD>	20150 003	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
>DLT>	~~20150 003~~	~~NICOTINE; NICOTROL~~	~~4915950~~	~~APR 10, 2007~~			
>ADD>	20165 001	NICOTINE; NICODERM	5364630	JUN 14, 2008			
>DLT>	~~20165 001~~	~~NICOTINE; NICODERM~~	~~5364630~~	~~APR 02, 2010~~			
>ADD>			5344656	JUN 14, 2008			
>DLT>			~~5344656~~	~~APR 02, 2008~~			
>ADD>			5342623	JUN 14, 2008			
>DLT>			~~5342623~~	~~APR 02, 2008~~			
>ADD>			5004610	JUN 14, 2008			
>DLT>			~~5004610~~	~~APR 02, 2008~~			
>ADD>	20165 002	NICOTINE; NICODERM	5364630	JUN 14, 2008			
>DLT>	~~20165 002~~	~~NICOTINE; NICODERM~~	~~5364630~~	~~APR 02, 2010~~			
>ADD>			5344656	JUN 14, 2008			
>DLT>			~~5344656~~	~~APR 02, 2008~~			
>ADD>			5342623	JUN 14, 2008			
>DLT>			~~5342623~~	~~APR 02, 2008~~			
>ADD>			5004610	JUN 14, 2008			
>DLT>			~~5004610~~	~~APR 02, 2008~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20165 003	NICOTINE; NICODERM	5364630	JUN 14, 2008			
>DLT>	~~20165 003~~	~~NICOTINE; NICODERM~~	~~5364630~~	~~APR 02, 2010~~			
>ADD>			5344656	JUN 14, 2008			
>DLT>			~~5344656~~	~~APR 02, 2008~~			
>ADD>			5342623	JUN 14, 2008			
>DLT>			~~5342623~~	~~APR 02, 2008~~			
>ADD>			5004610	JUN 14, 2008			
>DLT>			~~5004610~~	~~APR 02, 2008~~			
>ADD>	19684 001	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
>DLT>	~~19684 001~~	~~NIFEDIPINE; PROCARDIA XL~~	~~4327725~~	~~MAY 04, 1997~~			
>ADD>	19684 002	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
>DLT>	~~19684 002~~	~~NIFEDIPINE; PROCARDIA XL~~	~~4327725~~	~~MAY 04, 1997~~			
>ADD>	19684 003	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
>DLT>	~~19684 003~~	~~NIFEDIPINE; PROCARDIA XL~~	~~4327725~~	~~MAY 04, 1997~~			
	20198 001	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
>ADD>			4892741	JUN 08, 2008			
>DLT>			~~4892741~~	~~JAN 09, 2007~~			
	20198 002	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
>ADD>			4892741	JUN 08, 2008			
>DLT>			~~4892741~~	~~JAN 09, 2007~~			
	20198 003	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
>ADD>			4892741	JUN 08, 2008			
>DLT>			~~4892741~~	~~JAN 09, 2007~~			
>ADD>	20356 001	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008		NCE	FEB 02, 2000
>ADD>	20356 002	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008		NCE	FEB 02, 2000
>ADD>	20356 003	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008		NCE	FEB 02, 2000
>ADD>	20356 004	NISOLDIPINE; NISOCOR	4892741	JUN 08, 2008		NCE	FEB 02, 2000
>ADD>	20064 001	NITROFURANTOIN; MACROBID	4798725	JUN 16, 2006			
>DLT>	~~20064 001~~	~~NITROFURANTOIN; MACROBID~~	~~4798725~~	~~JAN 17, 2006~~			
>ADD>			4772473	JUN 16, 2006			
>DLT>			~~4772473~~	~~SEP 20, 2005~~			
	20145 001	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
	20145 002	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
	20145 003	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
	20145 004	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
	20145 005	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
	20145 006	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19508 001	NIZATIDINE; AXID	4375547	APR 12, 2002			
>DLT>	~~19508 001~~	~~NIZATIDINE; AXID~~	~~4375547~~	~~MAR 01, 2002~~			
>ADD>	19508 002	NIZATIDINE; AXID	4375547	APR 12, 2002			
>DLT>	~~19508 002~~	~~NIZATIDINE; AXID~~	~~4375547~~	~~MAR 01, 2002~~			
>ADD>	19384 002	NORFLOXACIN; NOROXIN	4639458	JAN 22, 2005			
>DLT>	~~19384 002~~	~~NORFLOXACIN; NOROXIN~~	~~4639458~~	~~JAN 27, 2004~~			
>ADD>	19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 14, 2003			
>DLT>	~~19757 001~~	~~NORFLOXACIN; CHIBROXIN~~	~~4551456~~	~~NOV 05, 2002~~			
>ADD>	20087 001	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
>DLT>	~~20087 001~~	~~OFLOXACIN; FLOXIN IN DEXTROSE 5%~~	~~4382892~~	~~MAY 10, 2000~~			
>ADD>	20087 002	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001			
>DLT>	~~20087 002~~	~~OFLOXACIN; FLOXIN~~	~~4382892~~	~~MAY 10, 2000~~			
>ADD>	20087 003	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001			
>DLT>	~~20087 003~~	~~OFLOXACIN; FLOXIN~~	~~4382892~~	~~MAY 10, 2000~~			
>ADD>	20087 004	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
>DLT>	~~20087 004~~	~~OFLOXACIN; FLOXIN IN DEXTROSE 5%~~	~~4382892~~	~~MAY 10, 2000~~			
>ADD>	20087 005	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
>DLT>	~~20087 005~~	~~OFLOXACIN; FLOXIN IN DEXTROSE 5%~~	~~4382892~~	~~MAY 10, 2000~~			
>ADD>	19810 001	OMEPRAZOLE; PRILOSEC	4853230	APR 20, 2007	U-108		
>DLT>	~~19810 001~~	~~OMEPRAZOLE; PRILOSEC~~	~~4853230~~	~~NOV 02, 2005~~	~~U-108~~		
>ADD>			4786505	APR 20, 2007	U-108	I-130	JUN 22, 1998
>DLT>			~~4786505~~	~~NOV 22, 2005~~	~~U-108~~	~~I-130~~	~~JUN 22, 1998~~
			4255431	MAR 10, 2000	U-108		
>ADD>	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44		
>DLT>	~~20007 001~~	~~ONDANSETRON HYDROCHLORIDE; ZOFRAN~~	~~4753789~~	~~JUN 28, 2005~~	~~U-44~~		
>ADD>			4695578	JAN 25, 2005		D-20	FEB 02, 1996
>DLT>			~~4695578~~	~~JAN 03, 2005~~		~~D-20~~	~~FEB 02, 1996~~
>ADD>	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44		
>DLT>	~~20103 001~~	~~ONDANSETRON HYDROCHLORIDE; ZOFRAN~~	~~4753789~~	~~JUN 28, 2005~~	~~U-44~~		
>ADD>			4695578	JAN 25, 2005		NCE	JAN 04, 1996
>DLT>			~~4695578~~	~~JAN 03, 2005~~		~~NCE~~	~~JAN 04, 1996~~
						D-27	APR 10, 1998
						I-9	APR 19, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44		
>DLT>	~~20103 002~~	~~ONDANSETRON HYDROCHLORIDE; ZOFRAN~~	~~4753789~~	~~JUN 28, 2005~~	~~U-44~~		
>ADD>			4695578	JAN 25, 2005		NCE	JAN 04, 1996
>DLT>			~~4695578~~	~~JAN 03, 2005~~		~~NCE~~	~~JAN 04, 1996~~
						D-27	APR 10, 1998
						I-9	APR 19, 1998
>ADD>	20403 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44	D-20	FEB 02, 1996
>DLT>	~~20403 001~~	~~ONDANSETRON HYDROCHLORIDE; ZOFRAN~~	~~4753789~~	~~JUN 28, 2005~~	~~U-44~~	~~D-20~~	~~FEB 02, 1996~~
>ADD>			4695578	JAN 25, 2005		NCE	JAN 04, 1996
>DLT>			~~4695578~~	~~JAN 03, 2005~~		~~NCE~~	~~JAN 04, 1996~~
						I-9	AUG 13, 1996
>ADD>	19828 001	OXICONAZOLE NITRATE; OXISTAT	4124767	DEC 27, 1996			
>ADD>	20209 001	OXICONAZOLE NITRATE; OXISTAT	4124767	DEC 27, 1996			
>ADD>	20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005			
>DLT>	~~20036 001~~	~~PAMIDRONATE DISODIUM; AREDIA~~	~~4711880~~	~~DEC 08, 2004~~			
>ADD>	20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005			
>DLT>	~~20036 003~~	~~PAMIDRONATE DISODIUM; AREDIA~~	~~4711880~~	~~DEC 08, 2004~~			
>ADD>	20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005			
>DLT>	~~20036 004~~	~~PAMIDRONATE DISODIUM; AREDIA~~	~~4711880~~	~~DEC 08, 2004~~			
>ADD>	19385 001	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
>DLT>	~~19385 001~~	~~PERGOLIDE MESYLATE; PERMAX~~	~~4797405~~	~~JAN 10, 2006~~			
>ADD>			4166182	FEB 08, 2000			
>DLT>			~~4166182~~	~~AUG 28, 1998~~			
>ADD>	19385 002	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
>DLT>	~~19385 002~~	~~PERGOLIDE MESYLATE; PERMAX~~	~~4797405~~	~~JAN 10, 2006~~			
>ADD>			4166182	FEB 08, 2000			
>DLT>			~~4166182~~	~~AUG 28, 1998~~			
>ADD>	19385 003	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
>DLT>	~~19385 003~~	~~PERGOLIDE MESYLATE; PERMAX~~	~~4797405~~	~~JAN 10, 2006~~			
>ADD>			4166182	FEB 08, 2000			
>DLT>			~~4166182~~	~~AUG 28, 1998~~			
>ADD>	17850 001	POTASSIUM CHLORIDE; KLOTRIX	4140756	JUN 10, 1996			
>DLT>	~~17850 001~~	~~POTASSIUM CHLORIDE; KLOTRIX~~	~~4140756~~	~~FEB 20, 1996~~			
>ADD>	18238 001	POTASSIUM CHLORIDE; MICRO-K	4259315	JUN 13, 2000			
>DLT>	~~18238 001~~	~~POTASSIUM CHLORIDE; MICRO-K~~	~~4259315~~	~~MAR 31, 1998~~			
>ADD>	18238 002	POTASSIUM CHLORIDE; MICRO-K 10	4259315	JUN 13, 2000			
>DLT>	~~18238 002~~	~~POTASSIUM CHLORIDE; MICRO-K 10~~	~~4259315~~	~~MAR 31, 1998~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19561 003	POTASSIUM CHLORIDE; MICRO-K LS	4259315	JUN 13, 2000			
>DLT>	~~19561 003~~	~~POTASSIUM CHLORIDE; MICRO-K LS~~	~~4259315~~	~~MAR 31, 1998~~			
>ADD>	19775 001	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	4327725	NOV 25, 2000			
>DLT>	~~19775 001~~	~~PRAZOSIN HYDROCHLORIDE; MINIPRESS XL~~	~~4327725~~	~~MAY 04, 1999~~			
>ADD>	19775 002	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	4327725	NOV 25, 2000			
>DLT>	~~19775 002~~	~~PRAZOSIN HYDROCHLORIDE; MINIPRESS XL~~	~~4327725~~	~~MAY 04, 1999~~			
>ADD>	18553 001	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
>DLT>	~~18553 001~~	~~PROPRANOLOL HYDROCHLORIDE; INDERAL LA~~	~~4138475~~	~~FEB 06, 1996~~			
>ADD>	18553 002	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
>DLT>	~~18553 002~~	~~PROPRANOLOL HYDROCHLORIDE; INDERAL LA~~	~~4138475~~	~~FEB 06, 1996~~			
>ADD>	18553 003	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
>DLT>	~~18553 003~~	~~PROPRANOLOL HYDROCHLORIDE; INDERAL LA~~	~~4138475~~	~~FEB 06, 1996~~			
>ADD>	19536 001	PROPRANOLOL HYDROCHLORIDE; INDERAL	4600708	JUL 19, 2005			
>DLT>	~~19536 001~~	~~PROPRANOLOL HYDROCHLORIDE; INDERAL~~	~~4600708~~	~~JUL 15, 2003~~			
>ADD>	19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	4929605	OCT 07, 2007	U-81		
>DLT>	~~19664 001~~	~~PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D~~	~~4929605~~	~~MAY 29, 2007~~	~~U-81~~		
>ADD>			4254129	APR 10, 1999	U-81		
>DLT>			~~4254129~~	~~MAR 03, 1998~~	~~U-81~~		
>ADD>	20021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; EFIDAC/24	4801461	MAR 14, 2006			
>DLT>	~~20021 002~~	~~PSEUDOEPHEDRINE HYDROCHLORIDE; EFIDAC/24~~	~~4801461~~	~~MAY 05, 2004~~			
>ADD>	19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007		I-92	OCT 29, 1996
>DLT>	~~19885 001~~	~~QUINAPRIL HYDROCHLORIDE; ACCUPRIL~~	~~4743450~~	~~MAY 10, 2005~~		~~I-92~~	~~OCT 29, 1996~~
>ADD>	19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007		I-92	OCT 29, 1996
>DLT>	~~19885 002~~	~~QUINAPRIL HYDROCHLORIDE; ACCUPRIL~~	~~4743450~~	~~MAY 10, 2005~~		~~I-92~~	~~OCT 29, 1996~~
>ADD>	19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007		I-92	OCT 29, 1996
>DLT>	~~19885 003~~	~~QUINAPRIL HYDROCHLORIDE; ACCUPRIL~~	~~4743450~~	~~MAY 10, 2005~~		~~I-92~~	~~OCT 29, 1996~~
>ADD>	19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007		I-92	OCT 29, 1996
>DLT>	~~19885 004~~	~~QUINAPRIL HYDROCHLORIDE; ACCUPRIL~~	~~4743450~~	~~MAY 10, 2005~~		~~I-92~~	~~OCT 29, 1996~~
	19901 001	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3		
	19901 002	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3		
	19901 003	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3		
	19901 004	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3		
>ADD>	18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4880636	MAY 13, 2008			
>ADD>			4128658	JUL 25, 1997		I-120	MAR 29, 1998
>DLT>			~~4128658~~	~~DEC 05, 1995~~		~~I-120~~	~~MAR 29, 1998~~

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4880636	MAY 13, 2008			
>ADD>			4128658	JUL 25, 1997			I-120 MAR 29, 1998
>DLT>			~~4128658~~	~~DEC 05, 1995~~			~~I-120 MAR 29, 1998~~
>ADD>	19090 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
>DLT>	~~19090 001~~	~~RANITIDINE HYDROCHLORIDE; ZANTAC~~	~~4585790~~	~~APR 29, 2003~~			
>ADD>			4128658	JUL 25, 1997			
>DLT>			~~4128658~~	~~DEC 05, 1995~~			
>ADD>	19593 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4128658	JUL 25, 1997			
>DLT>	~~19593 001~~	~~RANITIDINE HYDROCHLORIDE; ZANTAC~~	~~4128658~~	~~DEC 05, 1995~~			
>ADD>	19593 002	RANITIDINE HYDROCHLORIDE; ZANTAC	4128658	JUL 25, 1997			
>DLT>	~~19593 002~~	~~RANITIDINE HYDROCHLORIDE; ZANTAC~~	~~4128658~~	~~DEC 05, 1995~~			
>ADD>	19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			I-120 MAR 29, 1998
>DLT>	~~19675 001~~	~~RANITIDINE HYDROCHLORIDE; ZANTAC~~	~~4585790~~	~~APR 29, 2003~~			~~I-120 MAR 29, 1998~~
>ADD>			4128658	JUL 25, 1997			
>DLT>			~~4128658~~	~~DEC 05, 1995~~			
>ADD>	20095 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5028432	FEB 22, 2010			I-120 MAR 29, 1998
>DLT>	~~20095 001~~	~~RANITIDINE HYDROCHLORIDE; ZANTAC 150~~	~~5028432~~	~~JUL 02, 2008~~			~~I-120 MAR 29, 1998~~
>ADD>			4128658	JUL 25, 1997			
>DLT>			~~4128658~~	~~DEC 05, 1995~~			
>ADD>	20095 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	5028432	FEB 22, 2010			I-120 MAR 29, 1998
>DLT>	~~20095 002~~	~~RANITIDINE HYDROCHLORIDE; ZANTAC 300~~	~~5028432~~	~~JUL 02, 2008~~			~~I-120 MAR 29, 1998~~
>ADD>			4128658	JUL 25, 1997			
>DLT>			~~4128658~~	~~DEC 05, 1995~~			
>ADD>	20251 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	JUN 23, 2009			I-120 MAR 29, 1998
>DLT>	~~20251 001~~	~~RANITIDINE HYDROCHLORIDE; ZANTAC 150~~	~~5102665~~	~~APR 07, 2009~~			~~I-120 MAR 29, 1998~~
>ADD>			4128658	JUL 25, 1997			
>DLT>			~~4128658~~	~~DEC 05, 1995~~			
>ADD>	20251 002	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	JUN 23, 2009			I-120 MAR 29, 1998
>DLT>	~~20251 002~~	~~RANITIDINE HYDROCHLORIDE; ZANTAC 150~~	~~5102665~~	~~APR 07, 2009~~			~~I-120 MAR 29, 1998~~
>ADD>			4128658	JUL 25, 1997			
>DLT>			~~4128658~~	~~DEC 05, 1995~~			
>ADD>	20214 001	ROCURONIUM BROMIDE; ZEMURON (P/F)	4894369	APR 13, 2008			
>DLT>	~~20214 001~~	~~ROCURONIUM BROMIDE; ZEMURON (P/F)~~	~~4894369~~	~~JAN 16, 2007~~			
>ADD>	20214 002	ROCURONIUM BROMIDE; ZEMURON	4894369	APR 13, 2008			
>DLT>	~~20214 002~~	~~ROCURONIUM BROMIDE; ZEMURON~~	~~4894369~~	~~JAN 16, 2007~~			
>ADD>	20236 001	SALMETEROL XINAFOATE; SEREVENT	5380922	MAY 14, 2013			
>DLT>	~~20236 001~~	~~SALMETEROL XINAFOATE; SEREVENT~~	~~5380922~~	~~FEB 12, 2008~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
>DLT>	~~19839 001~~	~~SERTRALINE HYDROCHLORIDE; ZOLOFT~~	~~5248699~~	~~SEP 28, 2010~~	~~U-12~~		
>ADD>			4962128	NOV 02, 2009	U-12		
>DLT>			~~4962128~~	~~OCT 09, 2007~~	~~U-12~~		
>ADD>	19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
>DLT>	~~19839 002~~	~~SERTRALINE HYDROCHLORIDE; ZOLOFT~~	~~5248699~~	~~SEP 28, 2010~~	~~U-12~~		
>ADD>			4962128	NOV 02, 2009	U-12		
>DLT>			~~4962128~~	~~OCT 09, 2007~~	~~U-12~~		
>ADD>	19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
>DLT>	~~19839 003~~	~~SERTRALINE HYDROCHLORIDE; ZOLOFT~~	~~5248699~~	~~SEP 28, 2010~~	~~U-12~~		
>ADD>			4962128	NOV 02, 2009	U-12		
>DLT>			~~4962128~~	~~OCT 09, 2007~~	~~U-12~~		
>ADD>	19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
>DLT>	~~19839 004~~	~~SERTRALINE HYDROCHLORIDE; ZOLOFT~~	~~5248699~~	~~SEP 28, 2010~~	~~U-12~~		
>ADD>			4962128	NOV 02, 2009	U-12		
>DLT>			~~4962128~~	~~OCT 09, 2007~~	~~U-12~~		
>ADD>	20478 001	SEVOFLURANE; ULTANE				NCE	JUN 07, 2000
>ADD>	19766 001	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
>ADD>	19766 002	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
>ADD>	19766 003	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
>ADD>	19766 004	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	20240 001	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 002	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 003	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 004	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
>ADD>	20070 001	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
>DLT>	~~20070 001~~	~~TACRINE HYDROCHLORIDE; COGNEX~~	~~4816456~~	~~MAR 28, 2006~~	~~U-82~~		
>ADD>			4631286	OCT 25, 2004	U-97		
>DLT>			~~4631286~~	~~DEC 23, 2003~~	~~U-97~~		
>ADD>	20070 002	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
>DLT>	~~20070 002~~	~~TACRINE HYDROCHLORIDE; COGNEX~~	~~4816456~~	~~MAR 28, 2006~~	~~U-82~~		
>ADD>			4631286	OCT 25, 2004	U-97		
>DLT>			~~4631286~~	~~DEC 23, 2003~~	~~U-97~~		
>ADD>	20070 003	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
>DLT>	~~20070 003~~	~~TACRINE HYDROCHLORIDE; COGNEX~~	~~4816456~~	~~MAR 28, 2006~~	~~U-82~~		
>ADD>			4631286	OCT 25, 2004	U-97		
>DLT>			~~4631286~~	~~DEC 23, 2003~~	~~U-97~~		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20070 004	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
>DLT>	~~20070 004~~	~~TACRINE HYDROCHLORIDE; COGNEX~~	~~4816456~~	~~MAR 28, 2006~~	~~U-82~~		
>ADD>			4631286	OCT 25, 2004	U-97		
>DLT>			~~4631286~~	~~DEC 23, 2003~~	~~U-97~~		
>ADD>	19829 001	TECHNETIUM TC-99M EXAMETAZIME KIT; CERETEC	4615876	MAR 14, 2008		I-124	APR 07, 1998
>DLT>	~~19829 001~~	~~TECHNETIUM TC-99M EXAMETAZIME KIT; CERETEC~~	~~4789736~~	~~DEC 06, 2005~~		~~I-124~~	~~APR 07, 1998~~
>ADD>	19981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT; ULTRATAG	4755375	APR 17, 2008	U-51		
>DLT>	~~19981 001~~	~~TECHNETIUM TC-99M RED BLOOD CELL KIT; ULTRATAG~~	~~4755375~~	~~JUL 05, 2005~~	~~U-51~~		
>ADD>	19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
>DLT>	~~19057 001~~	~~TERAZOSIN HYDROCHLORIDE; HYTRIN~~	~~5412095~~	~~MAR 15, 2011~~			
>ADD>			5294615	APR 29, 2013			
>DLT>			~~5294615~~	~~MAR 15, 2011~~			
>ADD>			5212176	JUN 29, 2010			
>DLT>			~~5212176~~	~~MAY 18, 2010~~			
>ADD>			4112097	JAN 21, 1997	U-3		
>DLT>			~~4112097~~	~~SEP 05, 1995~~	~~U-3~~		
>ADD>	19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
>DLT>	~~19057 002~~	~~TERAZOSIN HYDROCHLORIDE; HYTRIN~~	~~5412095~~	~~MAR 15, 2011~~			
>ADD>			5294615	APR 29, 2013			
>DLT>			~~5294615~~	~~MAR 15, 2011~~			
>ADD>			5212176	JUN 29, 2010			
>DLT>			~~5212176~~	~~MAY 18, 2010~~			
>ADD>			4112097	JAN 21, 1997	U-3		
>DLT>			~~4112097~~	~~SEP 05, 1995~~	~~U-3~~		
>ADD>	19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
>DLT>	~~19057 003~~	~~TERAZOSIN HYDROCHLORIDE; HYTRIN~~	~~5412095~~	~~MAR 15, 2011~~			
>ADD>			5294615	APR 29, 2013			
>DLT>			~~5294615~~	~~MAR 15, 2011~~			
>ADD>			5212176	JUN 29, 2010			
>DLT>			~~5212176~~	~~MAY 18, 2010~~			
>ADD>			4112097	JAN 21, 1997	U-3		
>DLT>			~~4112097~~	~~SEP 05, 1995~~	~~U-3~~		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
>DLT>	~~19057 004~~	~~TERAZOSIN HYDROCHLORIDE; HYTRIN~~	~~5412095~~	~~MAR 15, 2011~~			
>ADD>			5294615	APR 29, 2013			
>DLT>			~~5294615~~	~~MAR 15, 2011~~			
>ADD>			5212176	JUN 29, 2010			
>DLT>			~~5212176~~	~~MAY 18, 2010~~			
>ADD>			4112097	JAN 21, 1997	U-3		
>DLT>			~~4112097~~	~~SEP 05, 1995~~	~~U-3~~		
>ADD>	20347 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
>DLT>	~~20347 001~~	~~TERAZOSIN HYDROCHLORIDE; HYTRIN~~	~~5412095~~	~~MAR 15, 2011~~			
>ADD>			5294615	APR 29, 2013			
>DLT>			~~5294615~~	~~MAR 15, 2011~~			
>ADD>			5212176	JUN 29, 2010			
>DLT>			~~5212176~~	~~MAY 18, 2010~~			
>ADD>			4112097	JAN 21, 1997			
>DLT>			~~4112097~~	~~SEP 05, 1995~~			
>ADD>	20347 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
>DLT>	~~20347 002~~	~~TERAZOSIN HYDROCHLORIDE; HYTRIN~~	~~5412095~~	~~MAR 15, 2011~~			
>ADD>			5294615	APR 29, 2013			
>DLT>			~~5294615~~	~~MAR 15, 2011~~			
>ADD>			5212176	JUN 29, 2010			
>DLT>			~~5212176~~	~~MAY 18, 2010~~			
>ADD>			4112097	JAN 21, 1997			
>DLT>			~~4112097~~	~~SEP 05, 1995~~			
>ADD>	20347 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
>DLT>	~~20347 003~~	~~TERAZOSIN HYDROCHLORIDE; HYTRIN~~	~~5412095~~	~~MAR 15, 2011~~			
>ADD>			5294615	APR 29, 2013			
>DLT>			~~5294615~~	~~MAR 15, 2011~~			
>ADD>			5212176	JUN 29, 2010			
>DLT>			~~5212176~~	~~MAY 18, 2010~~			
>ADD>			4112097	JAN 21, 1997			
>DLT>			~~4112097~~	~~SEP 05, 1995~~			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20347 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
>DLT>	20347 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	MAR 15, 2011			
>ADD>			5294615	APR 29, 2013			
>DLT>			5294615	MAR 15, 2011			
>ADD>			5212176	JUN 29, 2010			
>DLT>			5212176	MAY 18, 2010			
>ADD>			4112097	JAN 21, 1997			
>DLT>			4112097	SEP 05, 1995			
>ADD>	18949 001	TERFENADINE; SELDANE	4254129	APR 10, 1999	U-81		
>DLT>	18949 001	TERFENADINE; SELDANE	4254129	MAR 03, 1998	U-81		
>ADD>	19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003			
>DLT>	19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
>ADD>	19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003			
>DLT>	19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
	20439 001	TIMOLOL; BETIMOL	5231095	JUL 27, 2010		NP	MAR 31, 1998
	20439 002	TIMOLOL; BETIMOL	5231095	JUL 27, 2010		NP	MAR 31, 1998
>ADD>	20136 001	TORSEMIDE; DEMADEX	4822807	AUG 11, 2006			
>DLT>	20136 001	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
>ADD>	20136 002	TORSEMIDE; DEMADEX	4822807	AUG 11, 2006			
>DLT>	20136 002	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
>ADD>	20136 003	TORSEMIDE; DEMADEX	4822807	AUG 11, 2006			
>DLT>	20136 003	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
>ADD>	20136 004	TORSEMIDE; DEMADEX	4822807	AUG 11, 2006			
>DLT>	20136 004	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
>ADD>	20137 002	TORSEMIDE; DEMADEX	4822807	AUG 11, 2006			
>DLT>	20137 002	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
	20281 001	TRAMADOL HYDROCHLORIDE; ULTRAM				NCE	MAR 03, 2000
	20281 002	TRAMADOL HYDROCHLORIDE; ULTRAM				NCE	MAR 03, 2000
>ADD>	18207 003	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 26, 1999			
>DLT>	18207 003	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
>ADD>			4215104	MAR 26, 1999			
>DLT>			4215104	JUL 29, 1997			
>ADD>	18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 26, 1999			
>DLT>	18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
>ADD>			4215104	MAR 26, 1999			
>DLT>			4215104	JUL 29, 1997			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19798 001	TRIAMCINOLONE ACETONIDE; NASACORT	4767612	JAN 23, 2007	U-85		
>DLT>	~~19798 001~~	~~TRIAMCINOLONE ACETONIDE; NASACORT~~	~~4767612~~	~~AUG 30, 2005~~	~~U-85~~		
>ADD>	20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN	4694007	MAY 20, 2006	U-91		
>DLT>	~~20326 001~~	~~TRIMETREXATE GLUCURONATE; NEUTREXIN~~	~~4694007~~	~~SEP 15, 2004~~	~~U-91~~		
>ADD>			4376858	OCT 31, 2000			
>DLT>			~~4376858~~	~~MAR 15, 2000~~			
>ADD>	20487 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	AUG 04, 2008		NE	JUN 23, 1998
>ADD>	20487 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	AUG 04, 2008		NE	JUN 23, 1998
>ADD>	18776 002	VECURONIUM BROMIDE; NORCURON	4297351	AUG 20, 1999			
>DLT>	~~18776 002~~	~~VECURONIUM BROMIDE; NORCURON~~	~~4297351~~	~~OCT 27, 1998~~			
>ADD>			4237126	AUG 20, 1999			
>DLT>			~~4237126~~	~~DEC 02, 1997~~			
>ADD>	18776 003	VECURONIUM BROMIDE; NORCURON	4297351	AUG 20, 1999			
>DLT>	~~18776 003~~	~~VECURONIUM BROMIDE; NORCURON~~	~~4297351~~	~~OCT 27, 1998~~			
>ADD>			4237126	AUG 20, 1999			
>DLT>			~~4237126~~	~~DEC 02, 1997~~			
>ADD>	20151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
>DLT>	~~20151 001~~	~~VENLAFAXINE HYDROCHLORIDE; EFFEXOR~~	~~4535186~~	~~AUG 13, 2002~~			
>ADD>	20151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
>DLT>	~~20151 002~~	~~VENLAFAXINE HYDROCHLORIDE; EFFEXOR~~	~~4535186~~	~~AUG 13, 2002~~			
>ADD>	20151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
>DLT>	~~20151 003~~	~~VENLAFAXINE HYDROCHLORIDE; EFFEXOR~~	~~4535186~~	~~AUG 13, 2002~~			
>ADD>	20151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
>DLT>	~~20151 004~~	~~VENLAFAXINE HYDROCHLORIDE; EFFEXOR~~	~~4535186~~	~~AUG 13, 2002~~			
>ADD>	20151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
>DLT>	~~20151 005~~	~~VENLAFAXINE HYDROCHLORIDE; EFFEXOR~~	~~4535186~~	~~AUG 13, 2002~~			
>ADD>	20151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
>DLT>	~~20151 006~~	~~VENLAFAXINE HYDROCHLORIDE; EFFEXOR~~	~~4535186~~	~~AUG 13, 2002~~			
>ADD>	19614 001	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
>DLT>	~~19614 001~~	~~VERAPAMIL HYDROCHLORIDE; VERELAN~~	~~4863742~~	~~SEP 05, 2006~~	~~U-3~~		
>ADD>	19614 002	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
>DLT>	~~19614 002~~	~~VERAPAMIL HYDROCHLORIDE; VERELAN~~	~~4863742~~	~~SEP 05, 2006~~	~~U-3~~		
>ADD>	19614 003	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
>DLT>	~~19614 003~~	~~VERAPAMIL HYDROCHLORIDE; VERELAN~~	~~4863742~~	~~SEP 05, 2006~~	~~U-3~~		
	20388 001	VINORELBINE TARTRATE; NAVELBINE	4307100	DEC 22, 1998		NCE	DEC 23, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19655 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
>DLT>	~~19655 001~~	~~ZIDOVUDINE; RETROVIR~~	~~4837208~~	~~FEB 09, 2005~~			
>ADD>			4833130	SEP 17, 2005			
>DLT>			~~4833130~~	~~FEB 09, 2005~~			
>ADD>			4828838	SEP 17, 2005			
>DLT>			~~4828838~~	~~FEB 09, 2005~~			
>ADD>			4818538	SEP 17, 2005			
>ADD>			4724232	SEP 17, 2005			
>DLT>			~~4724232~~	~~FEB 09, 2005~~			
>ADD>	19910 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
>DLT>	~~19910 001~~	~~ZIDOVUDINE; RETROVIR~~	~~4837208~~	~~FEB 09, 2005~~			
>ADD>			4833130	SEP 17, 2005			
>DLT>			~~4833130~~	~~FEB 09, 2005~~			
>ADD>			4818538	SEP 17, 2005			
>DLT>			~~4818538~~	~~FEB 09, 2005~~			
>ADD>			4724232	SEP 17, 2005			
>DLT>			~~4724232~~	~~FEB 09, 2005~~			
>ADD>	19951 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
>DLT>	~~19951 001~~	~~ZIDOVUDINE; RETROVIR~~	~~4837208~~	~~FEB 09, 2005~~			
>ADD>			4833130	SEP 17, 2005			
>DLT>			~~4833130~~	~~FEB 09, 2005~~			
>ADD>			4818538	SEP 17, 2005			
>DLT>			~~4818538~~	~~FEB 09, 2005~~			
>ADD>			4724232	SEP 17, 2005			
>DLT>			~~4724232~~	~~FEB 09, 2005~~			

New 15th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7542

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

_ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $64.00 per year.

The total cost of my order is $_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

_____
(Purchase Order No.)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (10/94)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2233.
To charge your subscription call (202) 512-1800.

Library Use Only

Library Use Only

ST. LOUIS COLLEGE OF PHARMACY
3 2201 90036 5277

RM301.45 .A66 1995 Jun Suppl

Approved drug products with therapeutic equivalence
C:355661 M:174736 O:12937927